```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAPEZ1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 15   CAOLD to be discontinued on December 31, 2008
 NEWS  3  OCT 07   EPFULL enhanced with full implementation of EPC2000
 NEWS  4  OCT 07   Multiple databases enhanced for more flexible patent
                   number searching
 NEWS  5  OCT 22   Current-awareness alert (SDI) setup and editing
                   enhanced
 NEWS  6  OCT 22   WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                   Applications
 NEWS  7  OCT 24   CHEMLIST enhanced with intermediate list of
                   pre-registered REACH substances
 NEWS  8  NOV 21   CAS patent coverage to include exemplified prophetic
                   substances identified in English-, French-, German-,
                   and Japanese-language basic patents from 2004-present
 NEWS  9  NOV 26   MARPAT enhanced with FSORT command
 NEWS 10  NOV 26   MEDLINE year-end processing temporarily halts
                   availability of new fully-indexed citations
 NEWS 11  NOV 26   CHEMSAFE now available on STN Easy
 NEWS 12  NOV 26   Two new SET commands increase convenience of STN
                   searching
 NEWS 13  DEC 01   ChemPort single article sales feature unavailable
 NEWS 14  DEC 12   GBFULL now offers single source for full-text
                   coverage of complete UK patent families
 NEWS 15  DEC 17   Fifty-one pharmaceutical ingredients added to PS
 NEWS 16  JAN 06   The retention policy for unread STNmail messages
                   will change in 2009 for STN-Columbus and STN-Tokyo

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:58:41 ON 07 JAN 2009
```

```
=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.22       0.22

FILE 'REGISTRY' ENTERED AT 09:59:07 ON 07 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 JAN 2009  HIGHEST RN 1092767-60-6
DICTIONARY FILE UPDATES:   6 JAN 2009  HIGHEST RN 1092767-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10590724 elected.str
```



```
chain nodes :
7  8  10  11  12  18  25  26  27  28  29
ring nodes :
1  2  3  4  5  6  9  13  14  15  16  17  19  20  21  22  23  24
chain bonds :
3-10  5-7  6-11  7-8  8-9  8-29  11-12  16-18  18-19  21-25  25-26  25-28  26-27
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  9-13  9-17  13-14  14-15  15-16  16-17  19-20  19-24
20-21  21-22  22-23  23-24
exact/norm bonds :
```

5-7 6-11 7-8 8-29 11-12 16-18 18-19 25-26 25-28 26-27
exact bonds :
3-10 8-9 21-25
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-13 9-17 13-14 14-15 15-16 16-17 19-20 19-24
20-21 21-22 22-23 23-24

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS 28:CLASS
 29:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:59:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   24 TO ITERATE

100.0% PROCESSED   24 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 187 TO   773
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

```
=> s l1 sss ful
FULL SEARCH INITIATED 10:00:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      377 TO ITERATE

100.0% PROCESSED      377 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

L3            1 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     186.36     186.58

FILE 'CAPLUS' ENTERED AT 10:00:06 ON 07 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Jan 2009  VOL 150 ISS 2
FILE LAST UPDATED: 6 Jan 2009  (20090106/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4            1 L3

=> d l4

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2005:982303  CAPLUS
DN   143:286291
TI   Preparation of 2-pyridinecarboxamides as kinase inhibitors
IN   Burgorf, Lars; Buchstaller, Hans-Peter; Stieber, Frank; Amendt,
     Christiane; Greiner, Hartmut; Grell, Matthias; Sirrenberg, Christian;
     Zenke, Frank
PA   Merck Patent G.m.b.H., Germany
SO   Ger. Offen., 33 pp.
     CODEN: GWXXBX
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   DE 102004009238      A1    20050908    DE 2004-102004009238   20040226
```

```
     AU 2005219496         A1    20050915    AU 2005-219496          20050113
     CA 2557302            A1    20050915    CA 2005-2557302         20050113
     WO 2005085202         A1    20050915    WO 2005-EP273           20050113
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     EP 1718614            A1    20061108    EP 2005-700886          20050113
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     JP 2007523921         T     20070823    JP 2007-500077          20050113
     US 20070142440        A1    20070621    US 2006-590724          20060825
PRAI DE 2004-102004009238 A     20040226
     WO 2005-EP273         W     20050113
OS   MARPAT 143:286291


=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY    SESSION
FULL ESTIMATED COST                                3.75     190.33

STN INTERNATIONAL LOGOFF AT 10:03:22 ON 07 JAN 2009



Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAPEZ1617

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  AUG 15  CAOLD to be discontinued on December 31, 2008
 NEWS  3  OCT 07  EPFULL enhanced with full implementation of EPC2000
 NEWS  4  OCT 07  Multiple databases enhanced for more flexible patent
                  number searching
 NEWS  5  OCT 22  Current-awareness alert (SDI) setup and editing
                  enhanced
 NEWS  6  OCT 22  WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
                  Applications
 NEWS  7  OCT 24  CHEMLIST enhanced with intermediate list of
                  pre-registered REACH substances
 NEWS  8  NOV 21  CAS patent coverage to include exemplified prophetic
```

```
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  9  NOV 26  MARPAT enhanced with FSORT command
 NEWS 10  NOV 26  MEDLINE year-end processing temporarily halts
                  availability of new fully-indexed citations
 NEWS 11  NOV 26  CHEMSAFE now available on STN Easy
 NEWS 12  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS 13  DEC 01  ChemPort single article sales feature unavailable
 NEWS 14  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS 15  DEC 17  Fifty-one pharmaceutical ingredients added to PS
 NEWS 16  JAN 06  The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:08:00 ON 07 JAN 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:08:26 ON 07 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 JAN 2009  HIGHEST RN 1092767-60-6
DICTIONARY FILE UPDATES:   6 JAN 2009  HIGHEST RN 1092767-60-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10590724 generic.str





chain nodes :
7 8 15 22
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 16 17 18 19 20 21
chain bonds :
5-7 7-8 8-9 8-22 13-15 15-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 16-17 16-21
17-18 18-19 19-20 20-21
exact/norm bonds :
5-7 7-8 8-9 8-22 13-15 15-16 16-17 16-21 17-18 18-19 19-20 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 12:08:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7339 TO ITERATE

 27.3% PROCESSED     2000 ITERATIONS                              32 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       141644 TO   151916
PROJECTED ANSWERS:            1698 TO     2998

L2           32 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 12:08:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   145218 TO ITERATE

100.0% PROCESSED   145218 ITERATIONS                            2881 ANSWERS
SEARCH TIME: 00.00.04

L3         2881 SEA SSS FUL L1

=> fil cap
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               185.88     186.10

FILE 'CAPLUS' ENTERED AT 12:09:10 ON 07 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 7 Jan 2009 VOL 150 ISS 2
FILE LAST UPDATED: 6 Jan 2009 (20090106/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l3
L4         654 L3

=> s l4 and (py<2004 or ay<2004 or pry<2004)
      24034085 PY<2004
       4792818 AY<2004
       4264480 PRY<2004
L5         589 L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l5 and kinase inhibitor
         338645 KINASE
          63420 KINASES
         348962 KINASE
                (KINASE OR KINASES)
         601221 INHIBITOR
         593432 INHIBITORS
         931623 INHIBITOR
                (INHIBITOR OR INHIBITORS)
          45689 KINASE INHIBITOR
                (KINASE(W)INHIBITOR)
L6           27 L5 AND KINASE INHIBITOR

=> d scan

L6    27 ANSWERS   CAPLUS  COPYRIGHT 2009 ACS on STN
CC   28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
     Section cross-reference(s): 1, 63
TI   Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
ST   pyrazolopyrimidine prepn cyclin dependent kinase inhibitor CDK2 GSK3beta
     MAPK; antitumor pyrazolopyrimidine prepn
IT   Lymphoma
        (Burkett's; preparation of pyrazolopyrimidines as cyclin-dependent kinase
        inhibitors)
IT   Sarcoma
        (Kaposi's; preparation of pyrazolopyrimidines as cyclin-dependent kinase
        inhibitors)
IT   Neuroglia, neoplasm
        (astrocytoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase
        inhibitors)
IT   Antibodies and Immunoglobulins
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
        (co-administration with antibodies to EGFR; preparation of
        pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT   Cytotoxic agents
        (co-administration; preparation of pyrazolopyrimidines as cyclin-dependent
        kinase inhibitors)
```

IT Intestine, neoplasm
(colon; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Macrolides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epothilones, co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Sarcoma
(fibrosarcoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Thyroid gland, neoplasm
(follicle cell; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Neoplasm
(head and neck, treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Genetic element
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(intron, co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Skin, neoplasm
(keratoacanthoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT B-cell lymphoma
(mantle cell lymphoma, treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Astrocyte
(neoplasm, astrocytoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Schwann cell
(neoplasm, schwannoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Nerve, neoplasm
(neuroblastoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Bone, neoplasm
Sarcoma
(osteosarcoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT Acute myeloid leukemia
Acute promyelocytic leukemia
Antitumor agents
B-cell lymphoma
Bladder, neoplasm
Cervix, neoplasm
Chronic myeloid leukemia
Combination chemotherapy
Esophagus, neoplasm
Gallbladder, neoplasm
Hodgkin's disease
Human
Kidney, neoplasm
Leukemia
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Melanoma
Myelodysplastic syndromes
Neuroglia, neoplasm
Non-Hodgkin lymphoma
Ovary, neoplasm
Pancreas, neoplasm

Prostate gland, neoplasm
Skin, neoplasm
Small-cell lung carcinoma
Stomach, neoplasm
T-cell lymphoma
Thyroid gland, neoplasm
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Sarcoma
(rhabdomyosarcoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Nervous system, neoplasm
(schwannoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Testis, neoplasm
(seminoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Carcinoma
(squamous cell; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Carcinoma
(teratocarcinoma; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Head and Neck, neoplasm
Multiple myeloma
Neoplasm
Non-small-cell lung carcinoma
(treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Acute lymphocytic leukemia
(treatment of acute lymphocytic leukemia and acute lymphoblastic leukemia; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT Skin, disease
(xeroderma pigmentosum, treating; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 50-07-7 50-18-0 50-24-8 50-44-2 50-76-0, Actinomycin D 50-91-9
51-18-3 51-21-8 51-75-2 53-03-2 53-19-0 54-91-1 55-98-1
56-53-1 57-22-7 57-63-6 58-18-4 58-22-0 66-75-1 68-96-2
71-58-9 76-43-7 83-43-2 124-94-7 125-84-8 127-07-1 147-94-4
148-82-3 154-42-7 154-93-8 305-03-3 521-12-0 569-57-3 595-33-5
645-05-6 671-16-9 865-21-4, Vincaleukoblastine 968-93-4 2998-57-4
3778-73-2 4342-03-4 9015-68-3, Asparaginase 10540-29-1 11056-06-7,
Bleomycin 13010-47-4 13311-84-7 14769-73-4 15663-27-1 18378-89-7
18883-66-4 20830-81-3 23214-92-8 25316-40-9 29767-20-2
33069-62-4 33419-42-0 41575-94-4 51264-14-3 53643-48-4
53714-56-0 53910-25-1 56420-45-2 58957-92-9 61825-94-3
65271-80-9 65807-02-5 75607-67-9 85622-93-1 89778-26-7
95058-81-4 97682-44-5 114977-28-5 123948-87-8 154361-50-9
183319-69-9 184475-35-2 192185-68-5 193275-84-2 195987-41-8
220127-57-1 253863-00-2
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-administration; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 142805-58-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mapk/erk kinase; preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 141349-86-2 143375-65-9 443900-95-6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 672322-42-8P 779353-95-6P 934342-90-2P 1008793-86-9P 1008793-87-0P
RL: PAC (Pharmacological activity); PRPH (Prophetic); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 672315-17-2P 672315-22-9P 672315-47-8P 672315-98-9P 672316-00-6P
672316-20-0P 672316-21-1P 672316-22-2P 672316-23-3P 672316-24-4P
672316-47-1P 672316-48-2P 672316-49-3P 672316-50-6P 672316-51-7P
672316-53-9P 672316-54-0P 672316-56-2P 672316-58-4P 672316-59-5P
672316-61-9P 672316-63-1P 672316-64-2P 672316-65-3P 672316-67-5P
672317-02-1P 672317-21-4P 672317-23-6P 672317-24-7P 672317-26-9P
672317-27-0P 672317-29-2P 672317-30-5P 672317-34-9P 672317-36-1P
672317-38-3P 672317-40-7P 672317-41-8P 672317-75-8P 672317-77-0P
672317-82-7P 672317-97-4P 672318-41-1P 672318-77-3P 672318-99-9P
672319-13-0P 672319-14-1P 672319-19-6P 672319-26-5P 672319-95-8P
672320-02-4P 672320-04-6P 672321-14-1P 672321-36-7P 672321-41-4P
672321-43-6P 672321-49-2P 672321-50-5P 672321-58-3P 672321-62-9P
672322-21-3P 672322-25-7P 672322-30-4P 672322-31-5P 672322-32-6P
672322-34-8P 672322-36-0P 672322-38-2P 672322-39-3P 672322-40-6P
672322-41-7P 672323-76-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 672314-94-2P 672314-95-3P 672314-96-4P 672314-97-5P 672314-98-6P
672314-99-7P 672315-00-3P 672315-01-4P 672315-02-5P 672315-03-6P
672315-04-7P 672315-05-8P 672315-06-9P 672315-07-0P 672315-08-1P
672315-09-2P 672315-10-5P 672315-11-6P 672315-12-7P 672315-13-8P
672315-14-9P 672315-15-0P 672315-16-1P 672315-18-3P 672315-19-4P
672315-20-7P 672315-21-8P 672315-23-0P 672315-24-1P 672315-25-2P
672315-26-3P 672315-27-4P 672315-28-5P 672315-29-6P 672315-30-9P
672315-31-0P 672315-32-1P 672315-33-2P 672315-34-3P 672315-35-4P
672315-36-5P 672315-37-6P 672315-38-7P 672315-39-8P 672315-40-1P
672315-42-3P 672315-44-5P 672315-45-6P 672315-46-7P 672315-48-9P
672315-49-0P 672315-50-3P 672315-51-4P 672315-52-5P 672315-53-6P
672315-54-7P 672315-55-8P 672315-56-9P 672315-57-0P 672315-58-1P
672315-59-2P 672315-60-5P 672315-61-6P 672315-62-7P 672315-63-8P
672315-64-9P 672315-65-0P 672315-66-1P 672315-67-2P 672315-68-3P
672315-69-4P 672315-70-7P 672315-71-8P 672315-72-9P 672315-73-0P
672315-74-1P 672315-75-2P 672315-76-3P 672315-77-4P 672315-78-5P
672315-79-6P 672315-80-9P 672315-81-0P 672315-82-1P 672315-83-2P
672315-84-3P 672315-85-4P 672315-86-5P 672315-87-6P 672315-88-7P
672315-89-8P 672315-90-1P 672315-91-2P 672315-92-3P 672315-93-4P
672315-94-5P 672315-95-6P 672315-96-7P 672315-97-8P 672315-99-0P
672316-01-7P 672316-02-8P 672316-03-9P 672316-04-0P 672316-05-1P
672316-06-2P 672316-07-3P 672316-08-4P 672316-09-5P 672316-10-8P
672316-11-9P 672316-12-0P 672316-13-1P 672316-14-2P 672316-15-3P
672316-16-4P 672316-17-5P 672316-18-6P 672316-19-7P 672316-25-5P
672316-26-6P 672316-27-7P 672316-28-8P 672316-29-9P 672316-30-2P
672316-31-3P 672316-32-4P 672316-33-5P 672316-34-6P 672316-35-7P
672316-36-8P 672316-37-9P 672316-38-0P 672316-39-1P 672316-40-4P
672316-41-5P 672316-42-6P 672316-43-7P 672316-44-8P 672316-45-9P
672316-46-0P 672316-68-6P 672316-69-7P 672316-71-1P 672316-73-3P
672316-75-5P 672316-77-7P 672316-79-9P 672316-80-2P 672316-81-3P
672316-83-5P 672316-84-6P 672316-86-8P 672316-90-4P 672316-92-6P
672316-93-7P 672316-95-9P 672316-98-2P 672317-00-9P 672317-04-3P
672317-06-5P 672317-08-7P 672317-10-1P 672317-12-3P 672317-14-5P
672317-15-6P 672317-16-7P 672317-17-8P 672317-19-0P 672317-31-6P
672317-33-8P 672317-43-0P 672317-45-2P 672317-47-4P 672317-49-6P
672317-50-9P 672317-51-0P 672317-52-1P 672317-54-3P 672317-56-5P
672317-57-6P 672317-58-7P 672317-60-1P 672317-62-3P 672317-64-5P
672317-66-7P 672317-68-9P 672317-70-3P 672317-71-4P 672317-72-5P
672317-74-7P 672317-79-2P 672317-80-5P 672317-83-8P 672317-85-0P
672317-86-1P 672317-88-3P 672317-90-7P 672317-91-8P 672317-93-0P

672317-95-2P 672317-99-6P 672318-00-2P 672318-02-4P 672318-03-5P
672318-04-6P 672318-05-7P 672318-07-9P 672318-08-0P 672318-10-4P
672318-11-5P 672318-13-7P 672318-15-9P 672318-17-1P 672318-20-6P
672318-22-8P 672318-24-0P 672318-26-2P 672318-28-4P 672318-30-8P
672318-31-9P 672318-32-0P 672318-33-1P 672318-35-3P 672318-37-5P
672318-39-7P 672318-40-0P 672318-43-3P 672318-45-5P 672318-47-7P
672318-49-9P 672318-51-3P 672318-53-5P 672318-54-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 672318-56-8P 672318-58-0P 672318-60-4P 672318-61-5P 672318-63-7P
672318-64-8P 672318-66-0P 672318-68-2P 672318-70-6P 672318-72-8P
672318-74-0P 672318-76-2P 672318-79-5P 672318-81-9P 672318-82-0P
672318-84-2P 672318-85-3P 672318-87-5P 672318-88-6P 672318-90-0P
672318-92-2P 672318-94-4P 672318-95-5P 672318-97-7P 672319-01-6P
672319-03-8P 672319-05-0P 672319-07-2P 672319-09-4P 672319-11-8P
672319-15-2P 672319-17-4P 672319-18-5P 672319-21-0P 672319-23-2P
672319-25-4P 672319-28-7P 672319-30-1P 672319-32-3P 672319-34-5P
672319-35-6P 672319-37-8P 672319-39-0P 672319-40-3P 672319-42-5P
672319-44-7P 672319-46-9P 672319-48-1P 672319-49-2P 672319-51-6P
672319-53-8P 672319-54-9P 672319-55-0P 672319-56-1P 672319-58-3P
672319-60-7P 672319-62-9P 672319-64-1P 672319-66-3P 672319-67-4P
672319-69-6P 672319-71-0P 672319-73-2P 672319-76-5P 672319-77-6P
672319-78-7P 672319-80-1P 672319-82-3P 672319-84-5P 672319-86-7P
672319-88-9P 672319-89-0P 672319-90-3P 672319-91-4P 672319-93-6P
672319-97-0P 672320-00-2P 672320-06-8P 672320-08-0P 672320-10-4P
672320-11-5P 672320-12-6P 672320-14-8P 672320-16-0P 672320-18-2P
672320-20-6P 672320-22-8P 672320-24-0P 672320-26-2P 672320-27-3P
672320-28-4P 672320-29-5P 672320-32-0P 672320-33-1P 672320-35-3P
672320-37-5P 672320-39-7P 672320-40-0P 672320-41-1P 672320-43-3P
672320-45-5P 672320-47-7P 672320-48-8P 672320-50-2P 672320-51-3P
672320-53-5P 672320-55-7P 672320-56-8P 672320-57-9P 672320-59-1P
672320-61-5P 672320-63-7P 672320-65-9P 672320-66-0P 672320-67-1P
672320-69-3P 672320-71-7P 672320-73-9P 672320-75-1P 672320-76-2P
672320-78-4P 672320-80-8P 672320-82-0P 672320-84-2P 672320-85-3P
672320-87-5P 672320-89-7P 672320-91-1P 672320-92-2P 672320-94-4P
672320-96-6P 672320-98-8P 672320-99-9P 672321-00-5P 672321-01-6P
672321-03-8P 672321-04-9P 672321-05-0P 672321-07-2P 672321-09-4P
672321-11-8P 672321-12-9P 672321-16-3P 672321-17-4P 672321-19-6P
672321-21-0P 672321-23-2P 672321-25-4P 672321-26-5P 672321-28-7P
672321-29-8P 672321-30-1P 672321-32-3P 672321-34-5P 672321-38-9P
672321-39-0P 672321-45-8P 672321-46-9P 672321-47-0P 672321-52-7P
672321-54-9P 672321-56-1P 672321-60-7P 672321-64-1P 672321-65-2P
672321-66-3P 672321-67-4P 672321-69-6P 672321-71-0P 672321-72-1P
672321-74-3P 672321-76-5P 672321-78-7P 672321-80-1P 672321-82-3P
672321-83-4P 672321-85-6P 672321-87-8P 672321-88-9P 672321-90-3P
672321-92-5P 672321-93-6P 672321-95-8P 672321-97-0P 672321-99-2P
672322-00-8P 672322-02-0P 672322-04-2P 672322-05-3P 672322-07-5P
672322-09-7P 672322-10-0P 672322-12-2P 672322-14-4P 672322-16-6P
672322-17-7P 672322-19-9P 672322-20-2P 672322-23-5P 672322-27-9P
672322-29-1P 672322-44-0P 672322-46-2P 672322-48-4P 672322-50-8P
672322-52-0P 672322-53-1P 672322-54-2P 672322-55-3P 672322-57-5P
672322-59-7P 672322-61-1P 672322-62-2P 672322-64-4P 672322-66-6P
672322-68-8P 672322-70-2P 672322-72-4P 672322-73-5P 672322-74-6P
672322-75-7P 672322-76-8P 672322-78-0P 672322-80-4P 672322-82-6P
672322-83-7P 672322-85-9P 672322-87-1P 672322-89-3P 672322-91-7P
672322-93-9P 672322-94-0P 672322-95-1P 672322-96-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 672322-98-4P 672323-00-1P 672323-02-3P 672323-04-5P 677782-53-5P
677782-54-6P 677782-55-7P 677782-56-8P 677782-57-9P 677782-58-0P
677782-59-1P 677782-60-4P 677782-61-5P 677782-62-6P 677782-63-7P
677782-64-8P 677782-65-9P 677782-66-0P 677782-67-1P 677782-68-2P
677782-69-3P 677782-70-6P 677782-71-7P 677782-72-8P 677782-73-9P
677782-74-0P 677782-75-1P 677782-76-2P 677782-77-3P 677782-78-4P
677782-79-5P 677782-80-8P 677782-81-9P 677782-82-0P 677782-83-1P
677782-84-2P 677782-85-3P 677782-86-4P 677782-87-5P 677782-88-6P
677782-89-7P 677782-90-0P 677782-91-1P 677782-92-2P 677782-93-3P
677782-94-4P 677782-95-5P 677782-96-6P 677782-97-7P 677782-98-8P
677782-99-9P 677783-00-5P 677783-01-6P 677783-02-7P 677783-03-8P
677783-04-9P 677783-05-0P 677783-06-1P 677783-07-2P 677783-08-3P
677783-09-4P 677783-10-7P 677783-11-8P 677783-12-9P 677783-13-0P
677783-14-1P 677783-15-2P 677783-16-3P 677783-17-4P 677783-18-5P
677783-19-6P 677783-20-9P 677783-21-0P 677783-22-1P 677783-23-2P
677783-24-3P 677783-25-4P 677783-26-5P 677783-27-6P 677783-28-7P
677783-29-8P 677783-30-1P 677783-31-2P 677783-32-3P 677783-33-4P
677783-34-5P 677783-35-6P 677783-36-7P 677783-37-8P 677783-38-9P
677783-39-0P 677783-40-3P 677783-41-4P 677783-42-5P 677783-43-6P
677783-44-7P 677783-45-8P 677783-46-9P 677783-47-0P 677783-48-1P
677783-49-2P 677783-50-5P 677783-51-6P 677783-52-7P 677783-53-8P
677783-54-9P 677783-55-0P 677783-56-1P 677783-57-2P 677783-58-3P
677783-59-4P 677783-60-7P 677783-61-8P 677783-62-9P 677783-63-0P
677783-64-1P 677783-65-2P 677783-66-3P 677783-67-4P 677783-68-5P
677783-69-6P 677783-70-9P 677783-71-0P 677783-72-1P 677783-73-2P
677783-74-3P 677783-75-4P 677783-76-5P 677783-77-6P 677783-78-7P
677783-79-8P 677783-80-1P 677783-81-2P 677783-82-3P 677783-83-4P
677783-84-5P 677783-85-6P 677783-86-7P 677783-87-8P 677783-88-9P
677783-89-0P 677783-90-3P 677783-91-4P 677783-92-5P 677783-93-6P
677783-94-7P 677783-95-8P 677783-96-9P 677783-97-0P 677783-98-1P
677783-99-2P 677784-00-8P 677784-01-9P 677784-02-0P 677784-03-1P
677784-04-2P 677784-05-3P 677784-06-4P 677784-07-5P 677784-08-6P
677784-09-7P 677784-10-0P 677784-11-1P 677784-12-2P 677784-13-3P
677784-14-4P 677784-15-5P 677784-16-6P 677784-17-7P 677784-18-8P
677784-19-9P 677784-20-2P 677784-21-3P 677784-22-4P 677784-23-5P
677784-24-6P 677784-25-7P 677784-26-8P 677784-27-9P 677784-28-0P
677784-29-1P 677784-30-4P 677784-31-5P 677784-32-6P 677784-33-7P
677784-34-8P 677784-35-9P 677784-36-0P 677784-37-1P 677784-38-2P
677784-39-3P 677784-40-6P 677784-41-7P 677784-42-8P 677784-43-9P
677784-44-0P 677784-45-1P 677784-46-2P 677784-47-3P 677784-48-4P
677784-49-5P 677784-50-8P 677784-51-9P 677784-52-0P 677784-53-1P
677784-54-2P 677784-55-3P 677784-56-4P 677784-57-5P 677784-58-6P
677784-59-7P 677784-60-0P 677784-61-1P 677784-62-2P 677784-63-3P
677784-64-4P 677784-65-5P 677784-66-6P 677784-67-7P 677784-68-8P
677784-69-9P 677784-70-2P 677784-71-3P 677784-72-4P 677784-73-5P
677784-74-6P 677784-75-7P 677784-76-8P 677784-77-9P 677784-78-0P
677784-79-1P 677784-80-4P 677784-81-5P 677784-82-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 677784-83-7P 677784-84-8P 677784-85-9P 677784-86-0P 677784-87-1P
677784-88-2P 677784-89-3P 677784-90-6P 677784-91-7P 677784-92-8P
677784-93-9P 677784-94-0P 677784-95-1P 677784-96-2P 677784-97-3P
677784-98-4P 677784-99-5P 677785-00-1P 677785-01-2P 677785-02-3P
677785-03-4P 677785-04-5P 677785-05-6P 677785-06-7P 677785-07-8P
677785-08-9P 677785-09-0P 677785-10-3P 677785-11-4P 677785-12-5P
677785-13-6P 677785-14-7P 677785-15-8P 677785-16-9P 677785-17-0P
677785-18-1P 677785-19-2P 677785-20-5P 677785-21-6P 677785-22-7P
677785-23-8P 677785-24-9P 677785-25-0P 677785-26-1P 677785-27-2P
677785-28-3P 677785-29-4P 677785-30-7P 677785-31-8P 677785-32-9P
677785-33-0P 677785-34-1P 677785-35-2P 677785-36-3P 677785-37-4P

677785-38-5P 677785-39-6P 677785-40-9P 677785-41-0P 677785-42-1P
677785-43-2P 677785-44-3P 677785-45-4P 677785-46-5P 677785-47-6P
677785-48-7P 677785-49-8P 677785-50-1P 677785-51-2P 677785-52-3P
677785-53-4P 677785-54-5P 677785-56-7P 677785-58-9P 677785-60-3P
677785-62-5P 677785-64-7P 677785-66-9P 677785-68-1P 677785-70-5P
677785-72-7P 677785-74-9P 677785-76-1P 677785-78-3P 677785-80-7P
677785-82-9P 677785-83-0P 677785-84-1P 677785-85-2P 677785-86-3P
677785-87-4P 677785-88-5P 677785-89-6P 677785-90-9P 677785-92-1P
677785-94-3P 677785-96-5P 677785-97-6P 677785-99-8P 677786-00-4P
677786-01-5P 677786-02-6P 677786-03-7P 677786-04-8P 677786-05-9P
677786-06-0P 677786-07-1P 677786-08-2P 677786-09-3P 677786-10-6P
677786-11-7P 677786-12-8P 677786-13-9P 677786-14-0P 677786-15-1P
677786-16-2P 677786-17-3P 677786-18-4P 677786-19-5P 677786-20-8P
677786-21-9P 677786-22-0P 677786-23-1P 677786-24-2P 677786-25-3P
677786-26-4P 677786-27-5P 677786-28-6P 677786-29-7P 677786-30-0P
677786-31-1P 677786-32-2P 677786-33-3P 677786-34-4P 677786-35-5P
677786-36-6P 677786-37-7P 677786-38-8P 677786-39-9P 677786-40-2P
677786-41-3P 677786-42-4P 677786-43-5P 677786-44-6P 677786-45-7P
677786-46-8P 677786-47-9P 677786-48-0P 677786-49-1P 677786-50-4P
677786-51-5P 677786-52-6P 677786-53-7P 677786-54-8P 677786-55-9P
677786-56-0P 677786-57-1P 677786-58-2P 677786-59-3P 677786-60-6P
677786-61-7P 677786-62-8P 677786-63-9P 677786-64-0P 677786-65-1P
677786-66-2P 677786-67-3P 677786-68-4P 677786-69-5P 677786-70-8P
677786-71-9P 677786-72-0P 677786-73-1P 677786-74-2P 677786-75-3P
677786-76-4P 677786-77-5P 677786-78-6P 677786-79-7P 677786-80-0P
677786-81-1P 677786-82-2P 677786-83-3P 677786-84-4P 677786-85-5P
677786-86-6P 677786-87-7P 677786-88-8P 677786-89-9P 677786-90-2P
677786-91-3P 677786-92-4P 677786-93-5P 677786-94-6P 677786-95-7P
677786-96-8P 677786-97-9P 677786-98-0P 677786-99-1P 677787-00-7P
677787-01-8P 677787-02-9P 677787-03-0P 677787-04-1P 677787-05-2P
677787-06-3P 677787-07-4P 677787-08-5P 677787-09-6P 677787-10-9P
677787-11-0P 677787-12-1P 677787-13-2P 677787-14-3P 677787-15-4P
677787-16-5P 677787-17-6P 677787-18-7P 677787-19-8P 677787-20-1P
677787-21-2P 677787-22-3P 677787-23-4P 677787-24-5P 677787-25-6P
677787-26-7P 677787-27-8P 677787-28-9P 677787-29-0P 677787-30-3P
677787-31-4P 677787-32-5P 677787-33-6P 677787-34-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 677787-35-8P 677787-36-9P 677787-37-0P 677787-38-1P 677787-39-2P
677787-40-5P 677787-41-6P 677787-42-7P 677787-43-8P 677787-44-9P
677787-45-0P 677787-46-1P 677787-47-2P 677787-48-3P 677787-49-4P
677787-50-7P 677787-51-8P 677787-52-9P 677787-53-0P 677787-54-1P
677787-56-3P 677787-58-5P 677787-60-9P 677787-62-1P 677787-64-3P
677787-65-4P 677787-66-5P 677787-67-6P 677787-68-7P 677787-69-8P
677787-70-1P 677787-71-2P 677787-72-3P 677787-73-4P 677787-74-5P
677787-75-6P 677787-76-7P 677787-77-8P 677787-78-9P 677787-79-0P
677787-80-3P 677787-81-4P 677787-82-5P 677787-83-6P 677787-84-7P
677787-85-8P 677787-86-9P 677787-87-0P 677787-88-1P 677787-89-2P
677787-90-5P 677787-91-6P 677787-92-7P 677787-93-8P 677787-94-9P
677787-95-0P 677787-96-1P 677787-97-2P 677787-98-3P 677787-99-4P
677788-00-0P 677788-01-1P 677788-02-2P 677788-03-3P 677788-04-4P
677788-05-5P 677788-06-6P 677788-07-7P 677788-08-8P 677788-09-9P
677788-10-2P 677788-11-3P 677788-12-4P 677788-13-5P 677788-14-6P
677788-15-7P 677788-16-8P 677788-17-9P 677788-18-0P 677788-19-1P
677788-20-4P 677788-21-5P 677788-22-6P 677788-23-7P 677788-24-8P
677788-25-9P 677788-26-0P 677788-27-1P 677788-28-2P 677788-29-3P
677788-30-6P 677788-31-7P 677788-32-8P 677788-33-9P 677788-34-0P
677788-35-1P 677788-36-2P 677788-37-3P 677788-38-4P 677788-39-5P
677788-40-8P 677788-41-9P 677788-42-0P 677788-43-1P 677788-44-2P
677788-45-3P 677788-46-4P 677788-47-5P 677788-48-6P 677788-49-7P

677788-50-0P 677788-51-1P 677788-52-2P 677788-53-3P 677788-54-4P
677788-55-5P 677788-56-6P 677788-57-7P 677788-58-8P 677788-59-9P
677788-60-2P 677788-61-3P 677788-62-4P 677788-63-5P 677788-64-6P
677788-65-7P 677788-66-8P 677788-67-9P 677788-68-0P 677788-69-1P
677788-70-4P 677788-71-5P 677788-72-6P 677788-73-7P 677788-74-8P
677788-75-9P 677788-76-0P 677788-77-1P 677788-78-2P 677788-79-3P
677788-80-6P 677788-81-7P 677788-82-8P 677788-83-9P 677788-84-0P
677788-85-1P 677788-86-2P 677788-87-3P 677788-88-4P 677788-89-5P
677788-90-8P 677788-91-9P 677788-92-0P 677788-93-1P 677788-94-2P
677788-95-3P 677788-96-4P 677788-97-5P 677788-98-6P 677788-99-7P
677789-00-3P 677789-01-4P 677789-02-5P 677789-03-6P 677789-04-7P
677789-05-8P 677789-06-9P 677789-07-0P 677789-08-1P 677789-09-2P
677789-10-5P 677789-11-6P 677789-12-7P 677789-13-8P 677789-15-0P
677789-16-1P 677789-17-2P 677789-18-3P 677789-19-4P 677789-20-7P
677789-21-8P 677789-22-9P 677789-23-0P 677789-24-1P 677789-25-2P
677789-26-3P 677789-27-4P 677789-28-5P 677789-29-6P 677789-30-9P
677789-31-0P 677789-32-1P 677789-33-2P 677789-34-3P 677789-35-4P
677789-36-5P 677789-37-6P 677789-38-7P 677789-39-8P 677789-40-1P
677789-41-2P 677789-42-3P 677789-43-4P 677789-44-5P 677789-45-6P
677789-46-7P 677789-47-8P 677789-48-9P 677789-49-0P 677789-50-3P
677789-51-4P 677789-52-5P 677789-53-6P 677789-54-7P 677789-55-8P
677789-56-9P 677789-57-0P 677789-58-1P 677789-59-2P 677789-60-5P
677789-61-6P 677789-62-7P 677789-63-8P 677789-64-9P 677789-65-0P
677789-66-1P 677789-67-2P 677789-68-3P 677789-69-4P 677789-70-7P
677789-71-8P 677789-72-9P 677789-73-0P 677789-74-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 677789-75-2P 677789-76-3P 677789-77-4P 677789-78-5P 677789-79-6P
677789-80-9P 677789-81-0P 677789-82-1P 677789-83-2P 677789-84-3P
677789-85-4P 677789-86-5P 677789-87-6P 677789-88-7P 677789-89-8P
677789-90-1P 677789-91-2P 677789-92-3P 677789-93-4P 677789-94-5P
677789-95-6P 677789-96-7P 677789-97-8P 677789-98-9P 677789-99-0P
677790-00-0P 677790-01-1P 677790-02-2P 677790-03-3P 677790-04-4P
677790-05-5P 677790-06-6P 677790-07-7P 677790-08-8P 677790-09-9P
677790-10-2P 677790-11-3P 677790-12-4P 677790-13-5P 677790-14-6P
677790-15-7P 677790-16-8P 677790-17-9P 677790-18-0P 677790-19-1P
677790-20-4P 677790-21-5P 677790-22-6P 677790-23-7P 677790-24-8P
677790-25-9P 677790-26-0P 677790-27-1P 677790-28-2P 677790-29-3P
677790-30-6P 677790-31-7P 677790-32-8P 677790-33-9P 677790-34-0P
677790-35-1P 677790-36-2P 677790-37-3P 677790-38-4P 677790-39-5P
677790-40-8P 677790-41-9P 677790-42-0P 677790-43-1P 677790-44-2P
677790-45-3P 677790-46-4P 677790-47-5P 677790-48-6P 677790-49-7P
677790-50-0P 677790-51-1P 677790-52-2P 677790-53-3P 677790-54-4P
677790-55-5P 677790-56-6P 677790-57-7P 677790-58-8P 677790-59-9P
677790-60-2P 677790-61-3P 677790-62-4P 677790-63-5P 677790-64-6P
677790-65-7P 677790-66-8P 677790-67-9P 677790-68-0P 677790-69-1P
677790-70-4P 677790-71-5P 677790-72-6P 677790-73-7P 677790-74-8P
677790-75-9P 677790-76-0P 677790-77-1P 677790-78-2P 677790-79-3P
677790-80-6P 677790-81-7P 677790-82-8P 677790-83-9P 677790-84-0P
677790-85-1P 677790-86-2P 677790-87-3P 677790-88-4P 677790-89-5P
677790-90-8P 677790-91-9P 677790-92-0P 677790-93-1P 677790-94-2P
677790-95-3P 677790-96-4P 677790-97-5P 677790-98-6P 677790-99-7P
677791-00-3P 677791-01-4P 677791-02-5P 677791-03-6P 677791-04-7P
677791-05-8P 677791-06-9P 677791-07-0P 677791-08-1P 677791-09-2P
677791-10-5P 677791-11-6P 677791-12-7P 677791-13-8P 677791-14-9P
677791-15-0P 677791-16-1P 677791-17-2P 677791-18-3P 677791-19-4P
677791-20-7P 677791-21-8P 677791-22-9P 677791-23-0P 677791-24-1P
677791-25-2P 677791-26-3P 677791-27-4P 677791-28-5P 677791-29-6P
677791-30-9P 677791-31-0P 677791-32-1P 677791-33-2P 677791-34-3P
677791-35-4P 677791-36-5P 677791-37-6P 677791-38-7P 677791-39-8P

677791-40-1P 677791-41-2P 677791-42-3P 677791-43-4P 677791-44-5P
677791-45-6P 677791-46-7P 677791-47-8P 677791-48-9P 677791-49-0P
677791-50-3P 677791-51-4P 677791-52-5P 677791-53-6P 677791-54-7P
677791-55-8P 677791-56-9P 677791-57-0P 677791-58-1P 677791-59-2P
677791-60-5P 677791-61-6P 677791-62-7P 677791-63-8P 677791-64-9P
677791-65-0P 677791-66-1P 677791-67-2P 677791-68-3P 677791-69-4P
677791-70-7P 677791-71-8P 677791-72-9P 677791-73-0P 677791-74-1P
677791-75-2P 677791-76-3P 677791-77-4P 677791-78-5P 677791-79-6P
677791-80-9P 677791-81-0P 677791-82-1P 677791-83-2P 677791-84-3P
677791-85-4P 677791-86-5P 677791-87-6P 677791-88-7P 677791-89-8P
677791-90-1P 677791-91-2P 677791-92-3P 677791-93-4P 677791-94-5P
677791-95-6P 677791-96-7P 677791-97-8P 677791-98-9P 677791-99-0P
677792-00-6P 677792-01-7P 677792-02-8P 677792-03-9P 677792-04-0P
677792-05-1P 677792-06-2P 677792-07-3P 677792-08-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)
IT 677792-09-5P 677792-10-8P 677792-11-9P 677792-12-0P 677792-13-1P
677792-14-2P 677792-15-3P 677792-16-4P 677792-17-5P 677792-18-6P
677792-19-7P 677792-20-0P 677792-21-1P 677792-22-2P 677792-23-3P
677792-24-4P 677792-26-6P 677792-27-7P 677792-28-8P 677792-29-9P
677792-30-2P 677792-31-3P 677792-32-4P 677792-33-5P 677792-34-6P
677792-35-7P 677792-36-8P 677792-37-9P 677792-38-0P 677792-39-1P
677792-40-4P 677792-41-5P 677792-42-6P 677792-43-7P 677792-44-8P
677792-45-9P 677792-46-0P 677792-47-1P 677792-48-2P 677792-49-3P
677792-50-6P 677792-51-7P 677792-52-8P 677792-53-9P 677792-54-0P
677792-55-1P 677792-56-2P 677792-57-3P 677792-58-4P 677792-59-5P
677792-60-8P 677792-61-9P 677792-62-0P 677792-63-1P 677792-64-2P
677792-65-3P 677792-66-4P 677792-67-5P 677792-68-6P 677792-69-7P
677792-70-0P 677792-71-1P 677792-72-2P 677792-73-3P 677792-74-4P
677792-75-5P 677792-76-6P 677792-77-7P 677792-78-8P 677792-79-9P
677792-80-2P 677792-81-3P 677792-82-4P 677792-83-5P 677792-84-6P
677792-85-7P 677792-86-8P 677792-87-9P 677792-88-0P 677792-89-1P
677792-90-4P 677792-91-5P 677792-92-6P 677792-93-7P 677792-94-8P
677792-95-9P 677792-96-0P 677792-97-1P 677792-98-2P 677792-99-3P
677793-00-9P 677793-01-0P 677793-02-1P 677793-03-2P 677793-04-3P
677793-05-4P 677793-06-5P 677793-07-6P 677793-08-7P 677793-09-8P
677793-10-1P 677793-11-2P 677793-12-3P 677793-13-4P 677793-14-5P
677793-15-6P 677793-16-7P 677793-17-8P 677793-18-9P 677793-19-0P
677793-20-3P 677793-21-4P 677793-22-5P 677793-23-6P 677793-24-7P
677793-25-8P 677793-26-9P 677793-27-0P 677793-28-1P 677793-29-2P
677793-30-5P 677793-31-6P 677793-32-7P 677793-33-8P 677793-34-9P
677793-35-0P 677793-36-1P 677793-37-2P 677793-38-3P 677793-39-4P
677793-40-7P 677793-41-8P 677793-42-9P 677793-43-0P 677793-44-1P
677793-45-2P 677793-46-3P 677793-47-4P 677793-48-5P 677793-49-6P
677793-50-9P 677793-51-0P 677793-52-1P 677793-53-2P 677793-54-3P
677793-55-4P 677793-56-5P 677793-57-6P 677793-58-7P 677793-59-8P
677793-60-1P 677793-61-2P 677793-62-3P 677793-63-4P 677793-64-5P
677793-65-6P 677793-66-7P 677793-67-8P 677793-68-9P 677793-69-0P
677793-70-3P 677793-71-4P 677793-72-5P 677793-73-6P 677793-74-7P
677793-75-8P 677793-76-9P 677793-77-0P 677793-78-1P 677793-79-2P
677793-80-5P 677793-81-6P 677793-82-7P 677793-83-8P 677793-84-9P
677793-85-0P 677793-86-1P 677793-87-2P 677793-88-3P 677793-89-4P
677793-90-7P 677793-91-8P 677793-92-9P 677793-93-0P 677793-94-1P
677793-95-2P 677793-96-3P 677793-97-4P 677793-98-5P 677793-99-6P
677794-00-2P 677794-01-3P 677794-02-4P 677794-03-5P 677794-04-6P
677794-05-7P 677794-06-8P 677794-07-9P 677794-08-0P 677794-09-1P
677794-10-4P 677794-11-5P 677794-12-6P 677794-13-7P 677794-14-8P
677794-15-9P 677794-16-0P 677794-17-1P 677794-18-2P 677794-19-3P
677794-20-6P 677794-21-7P 677794-22-8P 677794-23-9P 677794-24-0P
677794-25-1P 677794-26-2P 677794-27-3P 677794-28-4P 677794-29-5P

677794-30-8P 677794-31-9P 677794-32-0P 677794-33-1P 677794-34-2P
677794-35-3P 677794-36-4P 677794-37-5P 677794-38-6P 677794-39-7P
677794-40-0P 677794-41-1P 677794-42-2P 677794-43-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 677794-44-4P 677794-45-5P 677794-46-6P 677794-47-7P 677794-48-8P
677794-49-9P 677794-50-2P 677794-51-3P 677794-52-4P 677794-53-5P
677794-54-6P 677794-55-7P 677794-56-8P 677794-57-9P 677794-58-0P
677794-59-1P 677794-60-4P 677794-61-5P 677794-62-6P 677794-63-7P
677794-64-8P 677794-65-9P 677794-66-0P 677794-67-1P 677794-68-2P
677794-69-3P 677794-70-6P 677794-71-7P 677794-72-8P 677794-73-9P
677794-74-0P 677794-75-1P 677794-76-2P 677794-77-3P 677794-78-4P
677794-79-5P 677794-80-8P 677794-81-9P 677794-82-0P 677794-83-1P
677794-84-2P 677794-85-3P 677794-86-4P 677794-87-5P 677794-88-6P
677794-89-7P 677794-90-0P 677794-91-1P 677794-92-2P 677794-93-3P
677794-94-4P 677794-95-5P 677794-96-6P 677794-97-7P 677794-98-8P
677794-99-9P 677795-00-5P 677795-01-6P 677795-02-7P 677795-03-8P
677795-04-9P 677795-05-0P 677795-06-1P 677795-07-2P 677795-08-3P
677795-09-4P 677795-10-7P 677795-11-8P 677795-12-9P 677795-13-0P
677795-14-1P 677795-15-2P 677795-16-3P 677795-17-4P 677795-18-5P
677795-19-6P 677795-20-9P 677795-21-0P 677795-22-1P 677795-23-2P
677795-24-3P 677795-25-4P 677795-26-5P 677795-27-6P 677795-28-7P
677795-29-8P 677795-30-1P 677795-31-2P 677795-32-3P 677795-33-4P
677795-34-5P 677795-35-6P 677795-36-7P 677795-37-8P 677795-38-9P
677795-39-0P 677795-40-3P 677795-41-4P 677795-42-5P 677795-43-6P
677795-44-7P 677795-45-8P 677795-46-9P 677795-47-0P 677795-48-1P
677795-49-2P 677795-50-5P 677795-51-6P 677795-52-7P 677795-53-8P
677795-54-9P 677795-55-0P 677795-56-1P 677795-57-2P 677795-58-3P
677795-59-4P 677795-60-7P 677795-61-8P 677795-62-9P 677795-63-0P
677795-64-1P 677795-65-2P 677795-66-3P 677795-67-4P 677795-68-5P
677795-69-6P 677795-70-9P 677795-71-0P 677795-72-1P 677795-73-2P
677795-74-3P 677795-75-4P 677795-76-5P 677795-77-6P 677795-78-7P
677795-79-8P 677795-80-1P 677795-81-2P 677795-82-3P 677795-83-4P
677795-84-5P 677795-85-6P 677795-86-7P 677795-87-8P 677795-88-9P
677795-89-0P 677795-90-3P 677795-91-4P 677795-92-5P 677795-93-6P
677795-94-7P 677795-95-8P 677795-96-9P 677795-97-0P 677795-98-1P
677795-99-2P 677796-00-8P 677796-01-9P 677796-02-0P 677796-03-1P
677796-04-2P 677796-05-3P 677796-06-4P 677796-07-5P 677796-08-6P
677796-09-7P 677796-10-0P 677796-11-1P 677796-12-2P 677796-13-3P
677796-14-4P 677796-15-5P 677796-16-6P 677796-17-7P 677796-18-8P
677796-19-9P 677796-20-2P 677796-21-3P 677796-22-4P 677796-23-5P
677796-24-6P 677796-25-7P 677796-26-8P 677796-27-9P 677796-28-0P
677796-29-1P 677796-30-4P 677796-31-5P 677796-32-6P 677796-33-7P
677796-34-8P 677796-35-9P 677796-36-0P 677796-37-1P 677796-38-2P
677796-39-3P 677796-40-6P 677796-41-7P 677796-42-8P 677796-43-9P
677796-44-0P 677796-45-1P 677796-46-2P 677796-47-3P 677796-48-4P
779353-01-4P 779353-02-5P 779353-03-6P 779353-04-7P 779353-05-8P
779353-06-9P 779353-07-0P 779353-08-1P 779353-09-2P 779353-10-5P
779353-11-6P 779353-12-7P 779353-13-8P 779353-14-9P 779353-15-0P
779353-16-1P 779353-17-2P 779353-18-3P 779353-19-4P 779353-20-7P
779353-21-8P 779353-22-9P 779353-23-0P 779353-24-1P 779353-25-2P
779353-26-3P 779353-27-4P 779353-28-5P 779353-29-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 779353-30-9P 779353-31-0P 779353-32-1P 779353-33-2P 779353-34-3P
779353-35-4P 779353-36-5P 779353-37-6P 779353-38-7P 779353-39-8P
779353-40-1P 779353-41-2P 779353-42-3P 779353-43-4P 779353-44-5P
779353-45-6P 779353-46-7P 779353-47-8P 779353-48-9P 779353-49-0P

779353-50-3P 779353-51-4P 779353-52-5P 779353-53-6P 779353-54-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 220904-92-7P 267413-25-2P, 1H-Indazole-5-methanamine 267874-51-1P
672325-34-7P 672325-35-8P 673475-70-2P 779353-77-4P 1008793-88-1P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 56-91-7 59-48-3 75-31-0, 2-Propanamine, reactions 75-64-9, reactions
89-75-8 94-02-0 98-80-6 98-88-4, Benzoyl chloride 100-46-9,
Benzenemethanamine, reactions 100-58-3 100-60-7 102-49-8 105-53-3
108-00-9 108-59-8 108-91-8, Cyclohexanamine, reactions 109-01-3
109-04-6 109-74-0, Butanenitrile 109-85-3 109-96-6 110-85-0,
Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8,
Morpholine, reactions 110-97-4 111-42-2, reactions 123-75-1,
Pyrrolidine, reactions 123-90-0, Thiomorpholine 124-68-5 138-39-6
139-02-6 141-43-5, reactions 141-78-6, Acetic acid ethyl ester,
reactions 156-87-6 288-32-4, 1H-Imidazole, reactions 352-13-6
494-52-0 617-89-0, 2-Furanmethanamine 622-40-2, 4-Morpholineethanol
677-22-5 765-30-0, Cyclopropanamine 822-55-9, 1H-Imidazole-5-methanol
930-45-0 930-69-8 931-15-7 931-16-8 931-50-0 934-28-1
1003-03-8, Cyclopentanamine 1003-09-4 1068-55-9 1099-45-2
1194-02-1 1436-60-8 1436-61-9 1449-46-3 1484-84-0,
2-Piperidineethanol 1710-98-1 1820-80-0, 1H-Pyrazol-3-amine
1989-53-3 2026-48-4 2133-40-6 2251-65-2 2450-71-7,
2-Propyn-1-amine 2516-34-9, Cyclobutanamine 2516-47-4,
Cyclopropanemethanamine 2577-48-2 2706-56-1, 2-Pyridineethanamine
2719-27-9, Cyclohexanecarbonyl chloride 2749-11-3 2786-07-4
2842-38-8 2905-60-4 2955-88-6, 1-Pyrrolidineethanol 3034-53-5
3082-64-2 3222-48-8 3433-37-2, 2-Piperidinemethanol 3535-37-3
3731-51-9, 2-Pyridinemethanamine 3731-52-0, 3-Pyridinemethanamine
3731-53-1, 4-Pyridinemethanamine 3789-59-1 4244-84-2 4276-09-9
4301-14-8 4393-16-2 4543-47-9, 3-Furanmethanamine 4795-29-3
5004-07-9 5271-67-0, 2-Thiophenecarbonyl chloride 5292-21-7,
Cyclohexaneacetic acid 5587-42-8 5625-67-2, 2-Piperazinone 5680-79-5
5691-15-6 5691-21-4 5908-62-3 5993-91-9 6168-72-5 6232-11-7
6271-78-9 6335-76-8 6575-24-2 6859-99-0, 3-Piperidinol 6921-34-2
6937-16-2 7154-66-7 7175-81-7 7486-35-3 7531-52-4 7583-53-1
10070-92-5, 5-Pyrimidinecarboxaldehyde 10314-98-4 10316-79-7
10472-24-9 13325-10-5 14273-46-2 16466-97-0 16617-46-2
17201-43-3 17413-10-4 17850-11-2 19847-10-0, 2-Pyrazinecarbonyl
chloride 20781-20-8 20980-22-7 21615-34-9 22526-47-2 22724-81-8
23356-96-9 23719-80-4 24717-01-9 25054-53-9,
1,3-Benzodioxole-5-carbonyl chloride 27489-62-9 28188-41-2
28250-37-5 28697-07-6 29364-29-2 29602-39-9 29840-56-0
30318-99-1 33797-51-2 35320-23-1 36489-03-9 39021-62-0
39546-32-2, 4-Piperidinecarboxamide 40172-95-0 40482-12-0
50901-42-3, 4-Pyridazinecarboxaldehyde 51387-90-7 55551-49-0
55745-74-9 56586-13-1 57260-73-8 59260-76-3 60419-23-0
64099-82-7 65873-72-5 66228-31-7 66401-62-5 67319-76-0,
1H-Imidazole-1-butanamine 68076-36-8 68832-13-3 69385-30-4
70258-19-4 70449-23-9 71581-92-5 72235-53-1 73874-95-0
74111-21-0 75178-96-0 78190-11-1 79286-74-1 80696-30-6
81881-74-5, 1H-Indole-5-methanamine 84025-81-0 84951-44-0 85459-20-7
87120-72-7 88675-25-6 89363-94-0 89364-31-8 90905-31-0
90905-32-1 97004-04-1 98593-51-2 101252-53-3 102619-05-6
106940-10-7 108467-99-8 108468-00-4 114715-38-7 114715-39-8
115576-91-5 117720-58-8 120538-52-5 120747-84-4 121492-06-6
122536-76-9 126747-14-6 131379-40-3 132664-85-8 133181-64-3
135132-34-2 137583-05-2 142643-29-6 144222-22-0 144222-23-1

147081-44-5 147081-49-0 150349-36-3 155742-57-7 162167-97-7
164648-60-6, 1H-Benzimidazole-6-methanamine 165528-81-4 173282-69-4
175205-49-9 177906-48-8 181657-56-7 181657-57-8 184637-48-7
188554-13-4 188755-01-3 195044-13-4 196929-78-9 197893-32-6
205318-52-1 213993-30-7 215305-98-9 216394-06-8 216394-07-9
216659-02-8 220298-96-4 228422-38-6 239482-98-5 250161-45-6
260794-33-0 282727-21-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 288309-53-5 304873-65-2 306934-88-3 308795-91-7 308796-24-9
312693-18-8 321309-35-7 321330-19-2,
2,1,3-Benzoxadiazole-5-methanamine 342029-20-3 343338-26-1
343338-28-3 370069-31-1 387350-39-2 540787-92-6 550369-61-4
672307-83-4 672325-00-7 672325-01-8 672325-02-9 672325-03-0
672325-04-1 672325-05-2 672325-06-3 672325-07-4 672325-08-5
672325-09-6 672325-10-9 672325-11-0 672325-12-1 672325-13-2
672325-14-3 672325-15-4 672325-16-5 672325-18-7 672325-19-8
672325-20-1 672325-21-2 672325-22-3 672325-23-4 672325-24-5
672325-25-6 672325-26-7 672325-27-8 672325-28-9 672325-29-0
672325-30-3 672325-31-4 672325-32-5 672325-33-6 672325-36-9
672325-37-0 672325-38-1 672325-39-2 672325-40-5 672325-41-6
672325-42-7 672325-43-8 672325-44-9 672325-45-0 672325-46-1
672325-47-2 672325-48-3 672325-49-4 672325-50-7 672325-51-8
672325-52-9 672325-53-0 672325-54-1 672325-55-2 672325-56-3
672325-57-4 672325-58-5 672325-59-6 672325-65-4 672325-66-5
672325-68-7 672325-70-1 672325-71-2 672325-74-5 672325-75-6
672325-76-7 672325-78-9 672325-83-6 672325-96-1 672326-19-1
672326-21-5 672326-27-1 672326-31-7 672326-35-1 672326-36-2
672326-37-3 747409-26-3 779353-74-1 779353-75-2 779353-76-3
779353-78-5 779353-82-1 954582-87-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 4687-37-0P 7149-42-0P 10406-24-3P 10406-25-4P 13374-30-6P
13374-31-7P 13669-10-8P 14613-37-7P 15961-46-3P 15971-92-3P
25372-03-6P 29274-13-3P 32111-34-5P 33149-25-6P 41607-95-8P
41886-04-8P 42460-90-2P 43024-14-2P 43024-15-3P 50671-05-1P
56622-54-9P 57489-70-0P 57489-77-7P 60868-41-9P 61098-37-1P
62124-77-0P 62718-28-9P 64127-44-2P 65113-25-9P 68327-03-7P
68327-04-8P 68419-38-5P 72851-86-6P 81581-27-3P 92053-25-3P
101498-88-8P 102297-41-6P 103639-57-2P 110295-94-8P 111080-65-0P
111080-66-1P 114040-06-1P 114524-22-0P 120747-85-5P 120747-86-6P
125732-13-0P 134149-19-2P 135132-35-3P 167414-75-7P 172348-74-2P
183958-56-7P 189017-89-8P 189018-29-9P 189018-71-1P 203436-48-0P
213764-26-2P 220324-83-4P 221121-45-5P 294647-97-5P 304873-62-9P
324570-25-4P 342412-64-0P 394734-84-0P 618446-34-7P 672323-06-7P
672323-07-8P 672323-09-0P 672323-11-4P 672323-13-6P 672323-15-8P
672323-17-0P 672323-19-2P 672323-21-6P 672323-22-7P 672323-23-8P
672323-25-0P 672323-26-1P 672323-27-2P 672323-29-4P 672323-30-7P
672323-32-9P 672323-34-1P 672323-36-3P 672323-37-4P 672323-39-6P
672323-40-9P 672323-41-0P 672323-43-2P 672323-44-3P 672323-46-5P
672323-47-6P 672323-49-8P 672323-51-2P 672323-53-4P 672323-55-6P
672323-56-7P 672323-57-8P 672323-59-0P 672323-61-4P 672323-63-6P
672323-64-7P 672323-66-9P 672323-68-1P 672323-70-5P 672323-72-7P
672323-74-9P 672323-75-0P 672323-78-3P 672323-80-7P 672323-81-8P
672323-82-9P 672323-84-1P 672323-86-3P 672323-88-5P 672323-89-6P
672323-91-0P 672323-94-3P 672323-95-4P 672323-97-6P 672323-99-8P
672324-01-5P 672324-03-7P 672324-05-9P 672324-07-1P 672324-09-3P
672324-11-7P 672324-13-9P 672324-15-1P 672324-17-3P 672324-19-5P
672324-21-9P 672324-23-1P 672324-25-3P 672324-27-5P 672324-28-6P
672324-30-0P 672324-31-1P 672324-32-2P 672324-34-4P 672324-36-6P
672324-38-8P 672324-39-9P 672324-41-3P 672324-42-4P 672324-43-5P
672324-45-7P 672324-46-8P 672324-47-9P 672324-49-1P 672324-51-5P

672324-53-7P 672324-55-9P 672324-57-1P 672324-59-3P 672324-61-7P
672324-63-9P 672324-65-1P 672324-66-2P 672324-68-4P 672324-69-5P
672324-71-9P 672324-73-1P 672324-75-3P 672324-77-5P 672324-80-0P
672324-82-2P 672324-83-3P 672324-84-4P 672324-85-5P 672324-86-6P
672324-87-7P 672324-88-8P 672324-89-9P 672324-90-2P 672324-91-3P
672324-92-4P 672324-93-5P 672324-94-6P 672324-95-7P 672324-96-8P
672324-97-9P 672324-98-0P 672324-99-1P 672325-60-9P 672325-61-0P
672325-62-1P 672325-63-2P 672325-64-3P 672325-72-3P 672325-73-4P
672325-80-3P 672325-85-8P 672325-87-0P 672325-89-2P 672325-92-7P
672325-94-9P 672326-00-0P 672326-02-2P 672326-04-4P 672326-06-6P
672326-08-8P 672326-10-2P 672326-14-6P 672326-16-8P 672326-33-9P
673475-51-9P 779353-55-8P 779353-56-9P 779353-57-0P 779353-58-1P
779353-59-2P 779353-60-5P 779353-61-6P 779353-62-7P 779353-63-8P
779353-64-9P 779353-65-0P 779353-66-1P 779353-67-2P 779353-68-3P
779353-69-4P 779353-70-7P 779353-71-8P 779353-72-9P 779353-73-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 52-24-4 58-05-9 1327-53-3, Arsenic oxide (As2O3) 68335-15-9, Hematoporphyrin D 71486-22-1 82413-20-5 82640-04-8 107868-30-4
112809-51-5 120511-73-1 125317-39-7 129453-61-8 174722-31-7
179324-69-7 180288-69-1 192391-48-3 205923-56-4 206181-63-7
216503-57-0 216974-75-3
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

IT 677278-50-1P 677278-51-2P 677278-52-3P 677278-53-4P 677278-54-5P
677278-55-6P 677278-56-7P 677278-57-8P 677278-58-9P 677278-59-0P
677278-60-3P 677278-61-4P 677278-62-5P 677278-63-6P 677278-64-7P
677278-65-8P 677278-66-9P 677278-67-0P 677278-68-1P 677278-69-2P
677278-70-5P 677278-71-6P 677278-72-7P 677278-73-8P 677278-74-9P
677278-75-0P 677278-76-1P 677278-77-2P 677278-78-3P 677278-79-4P
677278-80-7P 677278-81-8P 677278-82-9P 677278-83-0P 677278-84-1P
677278-85-2P 677278-86-3P 677278-87-4P 677278-88-5P 677278-89-6P
677278-90-9P 677278-91-0P 677278-92-1P 677278-93-2P 677278-94-3P
677278-95-4P 677278-96-5P 677278-97-6P 677278-98-7P 677278-99-8P
677279-00-4P 677279-01-5P 677279-02-6P 677279-03-7P 677279-04-8P
677279-05-9P 677279-06-0P 677279-07-1P 677279-08-2P 677279-09-3P
677279-10-6P 677279-11-7P 677279-12-8P 677279-13-9P 677279-14-0P
677279-15-1P 677279-16-2P 677279-17-3P 677279-18-4P 677279-19-5P
677279-20-8P 677279-21-9P 677279-22-0P 677279-23-1P 677279-24-2P
677279-25-3P 677279-26-4P 677279-27-5P 677279-28-6P 677279-29-7P
677279-30-0P 677279-31-1P 677279-32-2P 677279-33-3P 677279-34-4P
677279-35-5P 677279-36-6P 677279-37-7P 677279-38-8P 677279-39-9P
677279-40-2P 677279-41-3P 677279-42-4P 677279-43-5P 677279-44-6P
677279-45-7P 677279-46-8P 677279-47-9P 677279-48-0P 677279-49-1P
677279-50-4P 677279-51-5P 677279-52-6P 677279-53-7P 677279-54-8P
677279-55-9P 677279-56-0P 677279-57-1P 677279-58-2P 677279-59-3P
677279-60-6P 677279-61-7P 677279-62-8P 677279-63-9P 677279-64-0P
677279-65-1P 677279-66-2P 677279-67-3P 677279-68-4P 677279-69-5P
677279-70-8P 677279-71-9P 677279-72-0P 677279-73-1P 677279-74-2P
677279-75-3P 677279-76-4P 677279-77-5P 677279-78-6P 677279-79-7P
677279-80-0P 677279-81-1P 677279-82-2P 677279-83-3P 677279-84-4P
677279-85-5P 677279-86-6P 677279-87-7P 677279-88-8P 677279-89-9P
677279-90-2P 677279-91-3P 677279-92-4P 677279-93-5P 677279-94-6P
677279-95-7P 677279-96-8P 677279-97-9P 677279-98-0P 677279-99-1P
677280-00-1P 677280-01-2P 677280-02-3P 677280-03-4P 677280-04-5P
677280-05-6P 677280-06-7P 677280-07-8P 677280-08-9P 677280-09-0P
677280-10-3P 677280-11-4P 677280-12-5P 677280-13-6P 677280-14-7P
677280-15-8P 677280-16-9P 677280-17-0P 677280-18-1P 677280-19-2P
677280-20-5P 677280-21-6P 677280-22-7P 677280-23-8P 677280-24-9P
677280-25-0P 677280-26-1P 677280-27-2P 677280-28-3P 677280-29-4P
677280-30-7P 677280-31-8P 677280-32-9P 677280-33-0P 677280-34-1P

677280-35-2P 677280-36-3P 677280-37-4P 677280-38-5P 677280-39-6P
677280-40-9P 677280-41-0P 677280-42-1P 677280-43-2P 677280-44-3P
677280-45-4P 677280-46-5P 677280-47-6P 677280-48-7P 677280-49-8P
677280-50-1P 677280-51-2P 677280-52-3P 677280-53-4P 677280-54-5P
677280-55-6P 677280-56-7P 677280-57-8P 677280-58-9P 677280-59-0P
677280-60-3P 677280-61-4P 677280-62-5P 677280-63-6P 677280-64-7P
677280-65-8P 677280-66-9P 677280-67-0P 677280-68-1P 677280-69-2P
677280-70-5P 677280-71-6P 677280-72-7P 677280-73-8P 677280-74-9P
677280-75-0P 677280-76-1P 677280-77-2P 677280-78-3P 677280-79-4P
677280-80-7P 677280-81-8P 677280-82-9P 677280-83-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

IT 677280-84-1P 677280-85-2P 677280-86-3P 677280-87-4P 677280-88-5P
677280-89-6P 677280-90-9P 677280-91-0P 677280-92-1P 677280-93-2P
677280-94-3P 677280-95-4P 677280-96-5P 677280-97-6P 677280-98-7P
677280-99-8P 677281-00-4P 677281-01-5P 677281-02-6P 677281-04-8P
677281-05-9P 677281-06-0P 677281-07-1P 677281-08-2P 677281-09-3P
677281-10-6P 677281-11-7P 677281-12-8P 677281-13-9P 677281-14-0P
677281-15-1P 677281-16-2P 677281-17-3P 677281-18-4P 677281-19-5P
677281-20-8P 677281-21-9P 677281-22-0P 677281-23-1P 677281-24-2P
677281-25-3P 677281-26-4P 677281-27-5P 677281-28-6P 677281-29-7P
677281-30-0P 677281-31-1P 677281-32-2P 677281-33-3P 677281-34-4P
677281-35-5P 677281-36-6P 677281-37-7P 677281-38-8P 677281-39-9P
677281-40-2P 677281-41-3P 677281-42-4P 677281-43-5P 677281-44-6P
677281-45-7P 677281-46-8P 677281-47-9P 677281-48-0P 677281-49-1P
677281-50-4P 677281-51-5P 677281-52-6P 677281-53-7P 677281-54-8P
677281-55-9P 677281-56-0P 677281-57-1P 677281-58-2P 677281-59-3P
677281-60-6P 677281-61-7P 677281-62-8P 677281-63-9P 677281-64-0P
677281-65-1P 677281-66-2P 677281-67-3P 677281-68-4P 677281-69-5P
677281-70-8P 677281-71-9P 677281-72-0P 677281-73-1P 677281-74-2P
677281-75-3P 677281-76-4P 677281-77-5P 677281-78-6P 677281-79-7P
677281-80-0P 677281-81-1P 677281-82-2P 677281-83-3P 677281-84-4P
677281-85-5P 677281-86-6P 677281-87-7P 677281-88-8P 677281-89-9P
677281-90-2P 677281-91-3P 677281-92-4P 677281-93-5P 677281-94-6P
677281-95-7P 677281-96-8P 677281-97-9P 677281-98-0P 677281-99-1P
677282-00-7P 677282-01-8P 677282-02-9P 677282-03-0P 677282-04-1P
677282-05-2P 677282-06-3P 677282-07-4P 677282-08-5P 677282-09-6P
677282-10-9P 677282-11-0P 677282-12-1P 677282-13-2P 677282-14-3P
677282-15-4P 677282-16-5P 677282-17-6P 677282-18-7P 677282-19-8P
677282-20-1P 677282-21-2P 677282-22-3P 677282-23-4P 677282-24-5P
677282-25-6P 677282-26-7P 677282-27-8P 677282-28-9P 677282-29-0P
677282-30-3P 677282-31-4P 677282-32-5P 677282-33-6P 677282-34-7P
677282-35-8P 677282-36-9P 677282-37-0P 677282-38-1P 677282-39-2P
677282-40-5P 677282-41-6P 677282-42-7P 677282-43-8P 677282-44-9P
677282-45-0P 677282-46-1P 677282-47-2P 677282-48-3P 677282-49-4P
677282-50-7P 677282-51-8P 677282-52-9P 677282-53-0P 677282-54-1P
677282-55-2P 677282-56-3P 677282-57-4P 677282-58-5P 677282-59-6P
677282-60-9P 677282-61-0P 677282-62-1P 677282-63-2P 677282-64-3P
677282-65-4P 677282-66-5P 677282-67-6P 677282-68-7P 677282-69-8P
677282-70-1P 677282-71-2P 677282-72-3P 677282-73-4P 677282-74-5P
677282-75-6P 677282-76-7P 677282-77-8P 677282-78-9P 677282-79-0P
677282-80-3P 677282-81-4P 677282-82-5P 677282-83-6P 677282-84-7P
677282-85-8P 677282-86-9P 677282-87-0P 677282-88-1P 677282-89-2P
677282-90-5P 677282-91-6P 677282-92-7P 677282-93-8P 677282-94-9P
677282-95-0P 677282-96-1P 677282-97-2P 677282-98-3P 677282-99-4P
677283-00-0P 677283-01-1P 677283-02-2P 677283-03-3P 677283-04-4P
677283-05-5P 677283-06-6P 677283-07-7P 677283-08-8P 677283-09-9P
677283-10-2P 677283-11-3P 677283-12-4P 677283-13-5P 677283-14-6P
677283-15-7P 677283-16-8P 677283-17-9P 677283-18-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

IT 677283-19-1P 677283-20-4P 677283-21-5P 677283-22-6P 677283-23-7P
677283-24-8P 677283-25-9P 677283-26-0P 677283-27-1P 677283-28-2P
677283-29-3P 677283-30-6P 677283-31-7P 677283-32-8P 677283-33-9P
677283-34-0P 677283-35-1P 677283-36-2P 677283-37-3P 677283-38-4P
677283-39-5P 677283-40-8P 677283-41-9P 677283-42-0P 677283-43-1P
677283-44-2P 677283-45-3P 677283-46-4P 677283-47-5P 677283-48-6P
677283-49-7P 677283-50-0P 677283-51-1P 677283-52-2P 677283-53-3P
677283-54-4P 677283-55-5P 677283-56-6P 677283-57-7P 677283-58-8P
677283-59-9P 677283-60-2P 677283-61-3P 677283-62-4P 677283-63-5P
677283-64-6P 677283-65-7P 677283-66-8P 677283-67-9P 677283-68-0P
677283-69-1P 677283-70-4P 677283-71-5P 677283-72-6P 677283-73-7P
677283-74-8P 677283-75-9P 677283-76-0P 677283-77-1P 677283-78-2P
677283-79-3P 677283-80-6P 677283-81-7P 677283-82-8P 677283-83-9P
677283-84-0P 677283-85-1P 677283-86-2P 677283-87-3P 677283-88-4P
677283-89-5P 677283-90-8P 677283-91-9P 677283-92-0P 677283-93-1P
677283-94-2P 677283-95-3P 677283-96-4P 677283-97-5P 677283-98-6P
677283-99-7P 677284-00-3P 677284-01-4P 677284-02-5P 677284-03-6P
677284-04-7P 677284-05-8P 677284-06-9P 677284-07-0P 677284-08-1P
677284-09-2P 677284-10-5P 677284-11-6P 677284-12-7P 677284-13-8P
677284-14-9P 677284-15-0P 677284-16-1P 677284-17-2P 677284-18-3P
677284-19-4P 677284-20-7P 677284-21-8P 677284-22-9P 677284-23-0P
677284-24-1P 677284-25-2P 677284-26-3P 677284-27-4P 677284-28-5P
677284-29-6P 677284-30-9P 677284-31-0P 677284-32-1P 677284-33-2P
677284-34-3P 677284-35-4P 677284-36-5P 677284-37-6P 677284-38-7P
677284-39-8P 677284-40-1P 677284-41-2P 677284-42-3P 677284-43-4P
677284-44-5P 677284-45-6P 677284-46-7P 677284-47-8P 677284-48-9P
677284-49-0P 677284-50-3P 677284-51-4P 677284-52-5P 677284-53-6P
677284-54-7P 677284-55-8P 677284-56-9P 677284-57-0P 677284-58-1P
677284-59-2P 677284-60-5P 677284-61-6P 677284-62-7P 677284-63-8P
677284-64-9P 677284-65-0P 677284-66-1P 677284-67-2P 677284-68-3P
677284-69-4P 677284-70-7P 677284-71-8P 677284-72-9P 677284-73-0P
677284-74-1P 677284-75-2P 677284-76-3P 677284-77-4P 677284-78-5P
677284-79-6P 677284-80-9P 677284-81-0P 677284-82-1P 677284-83-2P
677284-84-3P 677284-85-4P 677284-86-5P 677284-87-6P 677284-88-7P
677284-89-8P 677284-90-1P 677284-91-2P 677284-92-3P 677284-93-4P
677284-94-5P 677284-95-6P 677284-96-7P 677284-97-8P 677284-98-9P
677284-99-0P 677285-00-6P 677285-01-7P 677285-02-8P 677285-03-9P
677285-04-0P 677285-05-1P 677285-06-2P 677285-07-3P 677285-08-4P
677285-09-5P 677285-10-8P 677285-11-9P 677285-12-0P 677285-13-1P
677285-14-2P 677285-15-3P 677285-16-4P 677285-17-5P 677285-18-6P
677285-19-7P 677285-20-0P 677285-21-1P 677285-22-2P 677285-23-3P
677285-24-4P 677285-25-5P 677285-26-6P 677285-27-7P 677285-28-8P
677285-29-9P 677285-30-2P 677285-31-3P 677285-32-4P 677285-33-5P
677285-34-6P 677285-35-7P 677285-36-8P 677285-37-9P 677285-38-0P
677285-39-1P 677285-40-4P 677285-41-5P 677285-42-6P 677285-43-7P
677285-44-8P 677285-45-9P 677285-46-0P 677285-47-1P 677285-48-2P
677285-49-3P 677285-50-6P 677285-51-7P 677285-52-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

IT 677285-53-9P 677285-54-0P 677285-55-1P 677285-56-2P 677285-57-3P
677285-58-4P 677285-59-5P 677285-60-8P 677285-61-9P 677285-62-0P
677285-63-1P 677285-64-2P 677285-65-3P 677285-66-4P 677285-67-5P
677285-68-6P 677285-69-7P 677285-70-0P 677285-71-1P 677285-72-2P
677285-73-3P 677285-74-4P 677285-75-5P 677285-76-6P 677285-77-7P

677285-78-8P 677285-79-9P 677285-80-2P 677285-81-3P 677285-82-4P
677285-83-5P 677285-84-6P 677285-85-7P 677285-86-8P 677285-87-9P
677285-88-0P 677285-89-1P 677285-90-4P 677285-91-5P 677285-92-6P
677285-93-7P 677285-94-8P 677285-95-9P 677285-96-0P 677285-97-1P
677285-98-2P 677285-99-3P 677286-00-9P 677286-01-0P 677286-02-1P
677286-03-2P 677286-04-3P 677286-05-4P 677286-06-5P 677286-07-6P
677286-08-7P 677286-09-8P 677286-10-1P 677286-11-2P 677286-12-3P
677286-13-4P 677286-14-5P 677286-15-6P 677286-16-7P 677286-17-8P
677286-18-9P 677286-19-0P 677286-20-3P 677286-21-4P 677286-22-5P
677286-23-6P 677286-24-7P 677286-25-8P 677286-26-9P 677286-27-0P
677286-28-1P 677286-29-2P 677286-30-5P 677286-31-6P 677286-32-7P
677286-33-8P 677286-34-9P 677286-35-0P 677286-36-1P 677286-37-2P
677286-38-3P 677286-39-4P 677286-40-7P 677286-41-8P 677286-42-9P
677286-43-0P 677286-44-1P 677286-45-2P 677286-46-3P 677286-47-4P
677286-48-5P 677286-49-6P 677286-50-9P 677286-51-0P 677286-52-1P
677286-53-2P 677286-54-3P 677286-55-4P 677286-56-5P 677286-57-6P
677286-58-7P 677286-59-8P 677286-60-1P 677286-61-2P 677286-62-3P
677286-63-4P 677286-64-5P 677286-65-6P 677286-66-7P 677286-67-8P
677286-68-9P 677286-70-3P 677286-71-4P 677286-72-5P 677286-73-6P
677286-74-7P 677286-75-8P 677286-76-9P 677286-77-0P 677286-78-1P
677286-79-2P 677286-80-5P 677286-81-6P 677286-82-7P 677286-83-8P
677286-84-9P 677286-85-0P 677286-86-1P 677286-87-2P 677286-88-3P
677286-89-4P 677286-90-7P 677286-91-8P 677286-92-9P 677286-93-0P
677286-94-1P 677286-95-2P 677286-96-3P 677286-97-4P 677286-98-5P
677286-99-6P 677287-00-2P 677287-01-3P 677287-02-4P 677287-03-5P
677287-04-6P 677287-05-7P 677287-06-8P 677287-07-9P 677287-08-0P
677287-09-1P 677287-10-4P 677287-11-5P 677287-12-6P 677287-13-7P
677287-14-8P 677287-15-9P 677287-16-0P 677287-17-1P 677287-18-2P
677287-19-3P 677287-20-6P 677287-21-7P 677287-22-8P 677287-23-9P
677287-24-0P 677287-25-1P 677287-26-2P 677287-27-3P 677287-28-4P
677287-29-5P 677287-30-8P 677287-31-9P 677287-32-0P 677287-33-1P
677287-34-2P 677287-35-3P 677287-36-4P 677287-37-5P 677287-38-6P
677287-39-7P 677287-40-0P 677287-41-1P 677287-42-2P 677287-43-3P
677287-44-4P 677287-45-5P 677287-46-6P 677287-47-7P 677287-48-8P
677287-49-9P 677287-50-2P 677287-51-3P 677287-52-4P 677287-53-5P
677287-54-6P 677287-55-7P 677287-56-8P 677287-57-9P 677287-58-0P
677287-59-1P 677287-60-4P 677287-61-5P 677287-62-6P 677287-63-7P
677287-64-8P 677287-65-9P 677287-66-0P 677287-67-1P 677287-68-2P
677287-69-3P 677287-70-6P 677287-71-7P 677287-72-8P 677287-73-9P
677287-74-0P 677287-75-1P 677287-76-2P 677287-77-3P 677287-78-4P
677287-79-5P 677287-80-8P 677287-81-9P 677287-82-0P 677287-83-1P
677287-84-2P 677287-85-3P 677287-86-4P 677287-87-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

IT 677287-88-6P 677287-89-7P 677287-90-0P 677287-91-1P 677287-92-2P
677287-93-3P 677287-94-4P 677287-95-5P 677287-96-6P 677287-97-7P
677287-98-8P 677287-99-9P 677288-00-5P 677288-01-6P 677288-02-7P
677288-03-8P 677288-04-9P 677288-05-0P 677288-06-1P 677288-07-2P
677288-08-3P 677288-09-4P 677288-10-7P 677288-11-8P 677288-12-9P
677288-13-0P 677288-14-1P 677288-15-2P 677288-16-3P 677288-17-4P
677288-18-5P 677288-19-6P 677288-20-9P 677288-21-0P 677288-22-1P
677288-23-2P 677288-24-3P 677288-25-4P 677288-26-5P 677288-27-6P
677288-28-7P 677288-29-8P 677288-30-1P 677288-31-2P 677288-32-3P
677288-33-4P 677288-34-5P 677288-35-6P 677288-36-7P 677288-37-8P
677288-38-9P 677288-39-0P 677288-40-3P 677288-41-4P 677288-42-5P
677288-43-6P 677288-44-7P 677288-45-8P 677288-46-9P 677288-47-0P
677288-48-1P 677288-49-2P 677288-50-5P 677288-51-6P 677288-52-7P
677288-53-8P 677288-54-9P 677288-55-0P 677288-56-1P 677288-57-2P
677288-58-3P 677288-59-4P 677288-60-7P 677288-61-8P 677288-62-9P

677288-63-0P 677288-64-1P 677288-65-2P 677288-66-3P 677288-67-4P
677288-68-5P 677288-69-6P 677288-70-9P 677288-71-0P 677288-72-1P
677288-73-2P 677288-74-3P 677288-75-4P 677288-76-5P 677288-77-6P
677288-78-7P 677288-79-8P 677288-80-1P 677288-81-2P 677288-82-3P
677288-83-4P 677288-84-5P 677288-85-6P 677288-86-7P 677288-87-8P
677288-88-9P 677288-89-0P 677288-90-3P 677288-91-4P 677288-92-5P
677288-93-6P 677288-94-7P 677288-95-8P 677288-96-9P 677288-97-0P
677288-98-1P 677288-99-2P 677289-00-8P 677289-01-9P 677289-02-0P
677289-03-1P 677289-04-2P 677289-05-3P 677289-06-4P 677289-07-5P
677289-08-6P 677289-09-7P 677289-10-0P 677289-11-1P 677289-12-2P
677289-13-3P 677289-14-4P 677289-15-5P 677289-16-6P 677289-17-7P
677289-18-8P 677289-19-9P 677289-20-2P 677289-21-3P 677289-22-4P
677289-23-5P 677289-24-6P 677289-25-7P 677289-26-8P 677289-27-9P
677289-28-0P 677289-29-1P 677289-30-4P 677289-31-5P 677289-32-6P
677289-33-7P 677289-34-8P 677289-35-9P 677289-36-0P 677289-37-1P
677289-38-2P 677289-39-3P 677289-40-6P 677289-41-7P 677289-42-8P
677289-43-9P 677289-44-0P 677289-45-1P 677289-46-2P 677289-47-3P
677289-48-4P 677289-49-5P 677289-50-8P 677289-51-9P 677289-52-0P
677289-53-1P 677289-54-2P 677289-55-3P 677289-56-4P 677289-57-5P
677289-58-6P 677289-59-7P 677289-60-0P 677289-61-1P 677289-62-2P
677289-63-3P 677289-64-4P 677289-65-5P 677289-66-6P 677289-67-7P
677289-68-8P 677289-69-9P 677289-70-2P 677289-71-3P 677289-72-4P
677289-73-5P 677289-74-6P 677289-75-7P 677289-76-8P 677289-77-9P
677289-78-0P 677289-79-1P 677289-80-4P 677289-81-5P 677289-82-6P
677289-83-7P 677289-84-8P 677289-85-9P 677289-86-0P 677289-87-1P
677289-88-2P 677289-89-3P 677289-90-6P 677289-91-7P 677289-92-8P
677289-93-9P 677289-94-0P 677289-95-1P 677289-96-2P 677289-97-3P
677289-98-4P 677289-99-5P 677290-00-5P 677290-01-6P 677290-02-7P
677290-03-8P 677290-04-9P 677290-05-0P 677290-06-1P 677290-07-2P
677290-08-3P 677290-09-4P 677290-10-7P 677290-11-8P 677290-12-9P
677290-13-0P 677290-14-1P 677290-15-2P 677290-16-3P 677290-17-4P
677290-18-5P 677290-19-6P 677290-20-9P 677290-21-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

IT 677290-22-1P 677290-23-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors for treating cancer)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d l6 1-27 ibib abs hitstr

L6 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1300802 CAPLUS
DOCUMENT NUMBER: 149:513860
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent S.; Fischmann, Thierry O.; Kirschmeier, Paul; Bannerji, Rajat; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhenmin; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas W.
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.

SOURCE: PCT Int. Appl., 635pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008130570	A1	20081030	WO 2008-US4907	20080416
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080050384	A1	20080228	US 2007-788847	20070420

PRIORITY APPLN. INFO.:

US 2007-788847	A	20070420
US 2002-408027P	P	20020904
US 2002-421959P	P	20021029
US 2003-654546	A2	20030903
US 2004-776988	A3	20040211
US 2006-396079	B2	20060331

OTHER SOURCE(S): MARPAT 149:513860
GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are claimed.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1300618 CAPLUS

DOCUMENT NUMBER: 149:513859

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.

PATENT ASSIGNEE(S): Schering Corporation, USA

SOURCE: PCT Int. Appl., 723pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008130569	A1	20081030	WO 2008-US4906	20080416
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20070281951	A1	20071206	US 2007-788856	20070420

PRIORITY APPLN. INFO.:		
US 2007-788856	A	20070420
US 2002-408027P	P	20020904
US 2002-421959P	P	20021029
US 2003-654546	A2	20030903
US 2004-776988	A2	20040211
US 2005-245401	A3	20051006
US 2007-710644	A2	20070223

OTHER SOURCE(S): MARPAT 149:513859

GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:251311 CAPLUS

DOCUMENT NUMBER: 148:308364

TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors

INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent S.; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhenmin; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh; Kirschmeier, Paul; Bannerji, Rajat

PATENT ASSIGNEE(S): Shering Corporation and Pharmacopeia, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 387 pp., Cont.-in-part of U.S. Ser. No. 396,079.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 10

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080050384	A1	20080228	US 2007-788847	20070420
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 20070054925	A1	20070308	US 2006-396079	20060331
WO 2008130570	A1	20081030	WO 2008-US4907	20080416

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2002-408027P	P	20020904
US 2002-421959P	P	20021029
US 2003-654546	A2	20030903
US 2004-776988	A3	20040211
US 2006-396079	B2	20060331
CN 2003-824997	A3	20030903
US 2007-788847	A	20070420

OTHER SOURCE(S): MARPAT 148:308364

GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are claimed.

L6 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1395785 CAPLUS
DOCUMENT NUMBER: 148:55084
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 497pp., Cont.-in-part of U.S. Ser. No. 710,644.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070281951	A1	20071206	US 2007-788856	20070420
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
US 20060128725	A1	20060615	US 2005-245401	20051006
US 7196078	B2	20070327		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 20070225270	A1	20070927	US 2007-710644	20070223
WO 2008130569	A1	20081030	WO 2008-US4906	20080416

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:		
US 2002-408027P	P	20020904
US 2002-421959P	P	20021029
US 2003-654546	A2	20030903
US 2004-776988	A2	20040211
US 2005-245401	A3	20051006
US 2007-710644	A2	20070223
CN 2003-824997	A3	20030903
US 2007-788856	A	20070420

OTHER SOURCE(S): MARPAT 148:55084
GI



I



III



II

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

L6 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1179520 CAPLUS
DOCUMENT NUMBER: 147:469333
TITLE: Inhibition of raf kinase using substituted heterocyclic ureas
INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko; Sibley, Robert; Renick, Joel
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 111pp., Div. of U.S. Ser. No. 640,780.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20070244120 A1 20071018 US 2007-768112 20070625 <--
PRIORITY APPLN. INFO.: US 2000-640780 A3 20000818 <--
OTHER SOURCE(S): MARPAT 147:469333
GI



II

AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-phenoxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temperature for 2 days gave 70% II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μM.

IT 228999-76-6P 229000-21-9P 229000-25-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 228999-76-6 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)



RN 229000-21-9 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 229000-25-3 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA

INDEX NAME)



L6 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:691680 CAPLUS
DOCUMENT NUMBER: 147:118041
TITLE: Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: U.S., 52pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 7235576	B1	20070626	US 2002-42203		20020111 <--
US 20030144278	A1	20030731	US 2002-283248		20021030 <--
US 20080108672	A1	20080508	US 2007-768104		20070625 <--
PRIORITY APPLN. INFO.:			US 2001-367380P	P	20010112 <--
			US 2002-42203	A1	20020111 <--

OTHER SOURCE(S): MARPAT 147:118041
AB Aryl ureas A-NHCONH-B [A, B = C5-40 (poly)aryl, optionally containing 0-4 N, O, S heteroatoms, optionally substituted by (hetero)aryl, (hetero)aryloxy, halo, cyano, nitro, alkoxy, alkylthio, amino, hydroxyalkyl, sulfo, acyl, carboxamido-groups], useful as Raf-kinase inhibitors for treatment and inhibition of cancerous cell growth, were prepared by standard synthetic procedures by reactions of the corresponding isocyanates with aromatic amines and tested for inhibition of Raf kinase and growth of human tumor cell lines HCT116 and DLD-1, exhibiting IC50 values of 1 nM to 10 μM. In an example, N-(4-chloro-3-trifluoromethylphenyl)-N'-[4-(2-methylaminocarbonyl-4-pyridinyloxy)phenyl]urea was prepared by reaction of 65.9 mmol of 4-chloro-3-trifluoromethylphenyl isocyanate with 65.77 mmol of 4-(2-methylaminocarbonyl-4-pyridinyloxy)aniline in CH2Cl2 at room temperature for 22 h with 93% yield.
IT 284461-67-2P 284461-68-3P 284461-70-7P
284462-09-5P 284462-10-8P 284462-15-3P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of carboxyaryl-substituted diarylureas as Raf kinase inhibitors for treatment and inhibition of cancerous cell growth)
RN 284461-67-2 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS
CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-
(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-
(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-
morpholinyl)phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-
(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)-
(CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-
(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-
(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 223 THERE ARE 223 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:962905 CAPLUS
DOCUMENT NUMBER: 147:211873
TITLE: Preparation of substituted heterocyclic ureas for inhibition of raf kinase
INVENTOR(S): Scott, William J.; Redman, Aniko; Johnson, Jeffrey; Wood, Jill E.; Paulsen, Holger; Khire, Uday; Dumas, Jacques; Smith, Roger A.; Lee, Wendy; Hatoum-Mokdad, Holia; Riedl, Bernd; Lowinger, Timothy Bruno
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: Aust. Pat. Appl., 148 pp., Division of Austl. 2003 204708.
CODEN: AUXXCM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
AU 2006201959	A1	20060601	AU 2006-201959		20060511 <--
AU 2006201959	B2	20080904			
AU 2003204708	A1	20030717	AU 2003-204708		20030613 <--
AU 2003204708	B2	20060525			
PRIORITY APPLN. INFO.:			AU 2003-204708	A3	20030613 <--
			AU 1999-21989	A3	19981222 <--
			WO 1998-US26078	W	19981222 <--

OTHER SOURCE(S): MARPAT 147:211873
GI



II

AB The title compds. ANHC(O)NHB [I; A = (un)substituted pyrazolyl, isoxazolyl, thienyl, etc.; B = (un)substituted Ph, pyridinyl, indolinyl, isoquinolinyl, etc.], useful in treating raf mediated diseases such as cancer, were prepared Thus, reacting 5-tert-butyl-3-thiophene-ammonium chloride with 4-phenoxyphenyl isocyanate in DMF afforded II. All exemplified compds. I displayed IC50 of between 1 nM and 10 μM when tested in in vitro raf kinase assay. Pharmaceutical composition comprising the compound I is disclosed.

IT 228999-76-6P 229000-21-9P 229000-25-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for inhibition of raf kinase)

RN 228999-76-6 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)



RN 229000-21-9 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 229000-25-3 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:579598 CAPLUS
DOCUMENT NUMBER: 145:62916
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 1068 pp., Cont.-in-part of U.S. Ser. No. 776,988.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060128725	A1	20060615	US 2005-245401	20051006
US 7196078	B2	20070327		
CN 1880317	A	20061220	CN 2006-10101322	20030903
US 7161003	B2	20070109	US 2003-654546	20030903
US 20070037824	A1	20070215		
US 20040209878	A1	20041021	US 2004-776988	20040211
US 7119200	B2	20061010		
ZA 2005001855	A	20060329	ZA 2005-1855	20060117
US 20070072881	A1	20070329	US 2006-542920	20061004
AU 2006302443	A1	20070419	AU 2006-302443	20061004
CA 2624829	A1	20070419	CA 2006-2624829	20061004
WO 2007044449	A2	20070419	WO 2006-US38939	20061004
WO 2007044449	A3	20070524		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1931677	A2	20080618	EP 2006-836186	20061004
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
US 20070225270	A1	20070927	US 2007-710644	20070223
US 20070281951	A1	20071206	US 2007-788856	20070420
IN 2008CN01697	A	20081226	IN 2008-CN1697	20080404
MX 200804665	A	20080617	MX 2008-4665	20080407

KR 2008063796	A	20080707	KR 2008-710183		20080428
CN 101321756	A	20081210	CN 2006-80045338		20080602
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904
			US 2002-421959P	P	20021029
			US 2003-654546	A2	20030903
			US 2004-776988	A2	20040211
			CN 2003-824997	A3	20030903
			US 2005-245401	A2	20051006
			WO 2006-US38939	W	20061004
			US 2007-710644	A2	20070223

OTHER SOURCE(S): MARPAT 145:62916
GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:470258 CAPLUS
DOCUMENT NUMBER: 143:1330
TITLE: Amide derivatives as kinase modulators, and their therapeutic use
INVENTOR(S): Mehta, Shamal A.; Grotzfeld, Robert M.; Milanov, Zdravko V.; Andiliy, Lai G.; Patel, Hitesh K.; Lockhart, David J.

PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA
SOURCE: PCT Int. Appl., 208 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005048953	A2	20050602	WO 2004-US38433	20041115 <--
WO 2005048953	A3	20060223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20050148605	A1	20050707	US 2004-989745	20041115 <--
US 20050165031	A1	20050728	US 2004-989814	20041115 <--
US 20050165024	A1	20050728	US 2004-989824	20041115 <--
US 20050165074	A1	20050728	US 2004-990007	20041115 <--
US 20050171171	A1	20050804	US 2004-989766	20041115 <--
US 20050171172	A1	20050804	US 2004-989823	20041115 <--
US 20050192314	A1	20050901	US 2004-990195	20041115 <--
US 20050197371	A1	20050908	US 2004-990194	20041115 <--
US 20050261315	A1	20051124	US 2004-989623	20041115 <--
US 20050267182	A1	20051201	US 2004-989717	20041115 <--
PRIORITY APPLN. INFO.:			US 2003-520273P P	20031113 <--
			US 2003-527094P P	20031203 <--
			US 2003-531082P P	20031218 <--
			US 2003-531243P P	20031218 <--

OTHER SOURCE(S): MARPAT 143:1330

AB The invention provides methods and compns. for treating conditions mediated by various kinases wherein derivs. of amide compds. are employed. The invention also provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects. Preparation of N-(3-tert-butylisoxazol-5-yl)-2-[4-(benzyloxy)phenyl]acetamide is described.

IT 1044667-71-1
RL: PRPH (Prophetic)
(Amide derivatives as kinase modulators, and their therapeutic use)

RN 1044667-71-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



L6 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:369222 CAPLUS
DOCUMENT NUMBER: 142:430279
TITLE: Preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors
INVENTOR(S): Lee, Dennis; Stavenger, Robert A.; Goodman, Krista B.; Hilfiker, Mark A.; Cui, Haifeng; Viet, Andrew Q.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005037197	A2	20050428	WO 2004-US32824		20041006 <--
WO 2005037197	A3	20050602			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1675552	A2	20060705	EP 2004-794238		20041006 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2007507546	T	20070329	JP 2006-534264		20041006 <--
US 20080234261	A1	20080925	US 2006-574676		20060404 <--
PRIORITY APPLN. INFO.:			US 2003-508894P	P	20031006 <--
			US 2003-531949P	P	20031223 <--
			WO 2004-US32824	W	20041006

OTHER SOURCE(S): CASREACT 142:430279; MARPAT 142:430279
GI



I



II



III

AB Title compds. I [wherein X = (un)substituted NH, O, S, SO or SO2; R1, R2 = (un)substituted alkyl, Ph, heteroaryl, etc.; and physiol. acceptable salts thereof] were prepared as Rho-kinase inhibitors. For example, 2,4-dichloro-5-nitropyridine (preparation given) underwent substitution with aniline (71% yield) and 3-acetylaminophenol (97% yield) subsequently followed by nitro reduction with H2 in the presence of Pd/C to give II (100% yield). Conversion of this compound into III was realized via EDCI-mediated coupling with cyanoacetic acid, thermal intramol. cyclization to an 2-imidazoeacetonitrile (65% yield for the two steps), reaction with NaNO2-HCl in methanol to an oxime (95% yield), and cyclization with NH2OH in the presence of Et3N (40% yield). The invented compds. are useful for the treatment of diseases, such as hypertension, heart failure and ischemic angina.

IT 850665-83-7P, N-[4-(Aminomethyl)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-20-5P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-21-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide 850666-22-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)phenyl]benzamide 850666-35-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]benzamide 850666-37-4P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(4-morpholinyl)phenyl]benzamide 850666-39-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(methyloxy)phenyl]benzamide 850666-58-9P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(4-morpholinyl)ethyl]oxy]phenyl]benzamide 850666-73-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[2-(dimethylamino)ethyl]oxy]phenyl]benzamide 850666-75-0P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[[3-(dimethylamino)propyl]oxy]phenyl]benzamide 850666-82-9P, N-[4-(Acetylamino)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850666-84-1P, N-[4-(Aminocarbonyl)phenyl]-3-[[2-(4-aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]benzamide 850667-16-2P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]benzamide 850667-36-6P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-

c]pyridin-6-yl]oxy]-N-[4-[(dimethylamino)methyl]phenyl]benzamide
850667-37-7P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethyl]phenyl]benzamide
850667-38-8P, 3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(inhibitor; preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors)

RN 850665-83-7 CAPLUS
CN Benzamide, N-[4-(aminomethyl)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)



RN 850666-20-5 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 850666-21-6 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 850666-22-7 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[3-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 850666-35-2 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 850666-37-4 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 850666-39-6 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 850666-58-9 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (CA INDEX NAME)



RN 850666-73-8 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethoxy]phenyl]- (CA INDEX NAME)



RN 850666-75-0 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[3-(dimethylamino)propoxy]phenyl]- (CA INDEX NAME)



RN 850666-82-9 CAPLUS
CN Benzamide, N-[4-(acetylamino)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)



RN 850666-84-1 CAPLUS
CN Benzamide, N-[4-(aminocarbonyl)phenyl]-3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]- (CA INDEX NAME)



RN 850667-16-2 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl]- (CA INDEX NAME)



RN 850667-36-6 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[(dimethylamino)methyl]phenyl]- (CA INDEX NAME)



RN 850667-37-7 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(dimethylamino)ethyl]phenyl]- (CA INDEX NAME)



RN 850667-38-8 CAPLUS
CN Benzamide, 3-[[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy]-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:29239 CAPLUS
DOCUMENT NUMBER: 142:134619
TITLE: Preparation of pyridinyl/pyridazinyloxymethyl substituted Raf kinase inhibitors
INVENTOR(S): Gill, Adrian Liam; Woodhead, Steven John; Woodhead, Andrew James; Frederickson, Martyn; Padova, Alessandro; Apaya, Robert Patrick
PATENT ASSIGNEE(S): Astex Technology Limited, UK
SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005002673	A1	20050113	WO 2004-GB2877	20040702 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-484300P P 20030703 <--
US 2003-484301P P 20030703 <--
OTHER SOURCE(S): MARPAT 142:134619
GI



I

AB Title compds. I [X=Y = CR2=CR3, CR2=N; R1 = H, halo, amino, etc.; R2-3 = H, alkyl, aryl, etc.; R4 = carboaryl, heteroaryl, etc.; R5 = halo, amino, etc.] are prepared For instance, 2-amino-3-benzyloxypyridine is prepared from 2-amino-3-hydroxypyridine and benzyl chloride. Over 180 examples are

provided. Selected example compds. have an IC50 < 1 μM for B-Raf kinase. I are useful in the treatment of a condition ameliorated by the inhibition of raf kinase, e.g., cancer.

IT 642085-16-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinyl/pyridazinyloxymethyl substituted Raf kinase inhibitors)

RN 642085-16-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[(2-pyrazinyloxy)methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1154653 CAPLUS
DOCUMENT NUMBER: 142:93545
TITLE: Preparation of diaryl ureas with kinase inhibiting activity
INVENTOR(S): Wilhelm, Scott; Dumas, Jacques; Ladouceur, Gaetan; Lynch, Mark; Scott, William J.
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113274	A2	20041229	WO 2004-US15655	20040519 <--
WO 2004113274	A3	20050303		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2526617	A1	20041229	CA 2004-2526617	20040519 <--
US 20050059703	A1	20050317	US 2004-848567	20040519 <--
EP 1636585	A2	20060322	EP 2004-752642	20040519 <--
EP 1636585	B1	20080116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007511203	T	20070510	JP 2006-533211	20040519 <--
AT 366108	T	20070715	AT 2004-776037	20040519 <--

ES 2288694	T3	20080116	ES 2004-776037		20040519 <--
AT 384264	T	20080215	AT 2004-752642		20040519 <--
ES 2305808	T3	20081101	ES 2004-752642		20040519 <--
MX 2005PA12491	A	20060929	MX 2005-PA12491		20051118 <--
US 20070020704	A1	20070125	US 2006-571100		20060728 <--
PRIORITY APPLN. INFO.:			US 2003-471735P	P	20030520 <--
			US 2003-520399P	P	20031117 <--
			US 2004-556062P	P	20040325
			WO 2004-US15655	W	20040519

OTHER SOURCE(S): MARPAT 142:93545

GI



I

AB Diaryl ureas B-NH-CO-NH-L-(CH2)m-X-(CH2)p-L1-(Q)1-3 [I; B = (un)substituted Ph, naphthyl, or heteroaryl; L, =(un)substituted Ph, naphthyl, or heteroaryl; X = bond, O, CO, NR3, NR3CO, S, CONR3, CF2, CCl2, CHF, CH(OH), C.tplbond.C, CH:CH, CR4R5; m, p = independently 0-4; L1 = any group L, 5-6 membered cyclic structure; Q = independently COR4, CO2R4, CONR4R5; each R3-R5 = independently H, (un)substituted C1-5 alkyl,C3-5 cycloalkyl, Ph, C1-3 alkylphenyl, C0-4 alkylheteroaryl], useful to treat diseases and conditions associated with signal transduction pathways comprising of at least one of raf, VEGFR, PDGFR, p38 and/or FLT-3. E.g., a multi-step synthesis of the urea II which produced dose-dependent 45-68% inhibition of tumor growth in a staged HCT 116 colon (mutant k-Ras) xenograft model.

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl ureas with kinase inhibiting activity)

RN 284461-67-2 CAPLUS

CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 284461-71-8 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1038664 CAPLUS
DOCUMENT NUMBER: 142:6556
TITLE: Preparation of substituted heterocycles for the treatment of abnormal cell growth
INVENTOR(S): Bhattacharya, Samit Kumar; Chen, Jinshan; Connell, Richard Damian; Kath, John Charles; Kauffman, Goss S.; Lippa, Blaise S.; Morris, Joel
PATENT ASSIGNEE(S): Pfizer Inc, USA
SOURCE: U.S. Pat. Appl. Publ., 54 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040242604	A1	20041202	US 2004-849707	20040520 <--
CA 2527017	A1	20041209	CA 2004-2527017	20040517 <--
WO 2004106308	A1	20041209	WO 2004-IB1687	20040517 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1636195	A1	20060322	EP 2004-733400		20040517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004010720	A	20060620	BR 2004-10720		20040517 <--
JP 2007501854	T	20070201	JP 2006-530679		20040517 <--
MX 2005PA12839	A	20060517	MX 2005-PA12839		20051128 <--
PRIORITY APPLN. INFO.:			US 2003-473817P	P	20030527 <--
			WO 2004-IB1687	W	20040517

OTHER SOURCE(S): CASREACT 142:6556; MARPAT 142:6556

GI



I

AB Title compds. I [Z = CR1, CCN, N; A = fused 5-7-membered ring optionally containing heteroatoms; R1 = H, alkyl; m = 0-3; p = 0-4; R3 = Ph, 4-6-membered heterocyclic ring; R4 = substituted divalent alkyl, etc.; R11 = halo, CN, NO2, etc.] are prepared For instance, N-tert-Butyl-4-[[2-methyl-4-[(6-(morpholin-4-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide is prepared in 8 steps from 6-fluoro-3H-pyrido[3,4-d]pyrimidin-4-one and 3-(4-amino-2-methylphenoxy)benzoic acid tert-Bu ester. Compds. of the invention have IC50 values of <10 μM against erbB-2 kinase. I are useful for treating abnormal cell growth.

IT 799242-89-0P, 3-[[4-[(6,7-Dimethoxyquinazolin-4-yl)amino]-2-methylphenyl]oxy]-N-(4-methoxyphenyl)benzamide 799242-90-3P, 3-[[4-[(6,7-Dimethoxyquinazolin-4-yl)amino]-2-methylphenyl]oxy]-N-(2-fluorophenyl)benzamide 799243-27-9P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-(morpholin-4-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide 799243-38-2P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-[[2-(morpholin-4-yl)ethyl]amino]pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide 799243-43-9P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-(4-methylpiperazin-1-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide 799243-47-3P, N-(2-Fluorophenyl)-3-[[2-methyl-4-[(6-(pyrrolidin-1-yl)pyrido[3,4-d]pyrimidin-4-yl)amino]phenyl]oxy]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted pyrimidine/quinazolines for treatment of abnormal cell growth)

RN 799242-89-0 CAPLUS

CN Benzamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenoxy]-N-(4-methoxyphenyl)- (CA INDEX NAME)



RN 799242-90-3 CAPLUS
CN Benzamide, 3-[4-[(6,7-dimethoxy-4-quinazolinyl)amino]-2-methylphenoxy]-N-(2-fluorophenyl)- (CA INDEX NAME)



RN 799243-27-9 CAPLUS
CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-(4-morpholinyl)pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)



RN 799243-38-2 CAPLUS
CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-[[2-(4-morpholinyl)ethyl]amino]pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)



RN 799243-43-9 CAPLUS
CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-(4-methyl-1-piperazinyl)pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)



RN 799243-47-3 CAPLUS
CN Benzamide, N-(2-fluorophenyl)-3-[2-methyl-4-[[6-(1-pyrrolidinyl)pyrido[3,4-d]pyrimidin-4-yl]amino]phenoxy]- (CA INDEX NAME)



L6 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:980998 CAPLUS
DOCUMENT NUMBER: 141:379942
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh

PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20040209878	A1	20041021	US 2004-776988		20040211	<--
US 20040209878	A1	20041021	US 2004-776988		20040211	<--
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904	<--
			US 2002-421959P	P	20021029	<--
			US 2003-654546	A2	20030903	<--
			US 2004-776988	A	20040211	

GI



I



II



III

AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 677786-82-2P 677787-26-7P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677786-82-2 CAPLUS

CN Benzamide, N-[4-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 677787-26-7 CAPLUS

CN Benzamide, N-[3-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



L6 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:265847 CAPLUS
DOCUMENT NUMBER: 140:321370
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 609 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004022561	A1	20040318	WO 2003-XA27555		20030903 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CN 1735614	A	20060215	CN 2003-824997		20030903 <--
CN 100376580	C	20080326			
CN 1880317	A	20061220	CN 2006-10101322		20030903 <--
ZA 2005001855	A	20060329	ZA 2005-1855		20060117 <--
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904 <--
			US 2002-421959P	P	20021029 <--
			CN 2003-824997	A3	20030903 <--

GI



I



II



III

AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 677786-82-2P 677787-26-7P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677786-82-2 CAPLUS

CN Benzamide, N-[4-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 677787-26-7 CAPLUS
CN Benzamide, N-[3-[[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



L6 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:41269 CAPLUS
DOCUMENT NUMBER: 140:77038
TITLE: Preparation of 3-[heteroarylmethoxy]pyridines and their analogues as p38 map kinase inhibitors
INVENTOR(S): Murray, Christopher William; Hartshorn, Michael John; Frederickson, Martyn; Congreve, Miles Stuart; Padova, Alessandro; Woodhead, Steven John; Gill, Adrian Liam; Woodhead, Andrew James
PATENT ASSIGNEE(S): Astex Technology Limited, UK
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004720	A1	20040115	WO 2003-GB2864	20030703 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003246927	A1	20040123	AU 2003-246927	20030703 <--
EP 1545523	A1	20050629	EP 2003-762777	20030703 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538975	T	20051222	JP 2004-518947	20030703 <--
US 20060063782	A1	20060323	US 2005-519922	20050103 <--

PRIORITY APPLN. INFO.:

GB 2002-15383	A	20020703 <--
US 2002-393121P	P	20020703 <--
GB 2002-26149	A	20021108 <--
WO 2003-GB2864	W	20030703 <--

OTHER SOURCE(S): MARPAT 140:77038
GI



I

AB Title compds. I [X=Y = CR2=CR3, CR2=N; R1 = H, halo, amino, etc.; R2-3 = H, alkyl, aryl, etc.; R4 = carboaryl, heteroaryl; R5 = halo, amino, carboxamido, etc.] are prepared For instance, 2-amino-3-benzyloxypyridine is prepared by alkylation of 2-amino-3-hydroxypyridine with benzyl chloride. A related example, 2-amino-3-[2-phenylbenzyloxy]pyridine has IC50 < 10μM for p38 map kinase. I are useful in the treatment of diseases ameliorated by inhibiting p38 MAP kinase.
IT 642085-16-3P, N-[4-Fluoro-3-(pyrazin-2-yloxymethyl)phenyl]-3-phenoxybenzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-[heteroarylmethoxy]pyridines and their analogs as p38 map kinase inhibitors for treatment of arthritis)

RN 642085-16-3 CAPLUS

CN Benzamide, N-[4-fluoro-3-[(2-pyrazinyloxy)methyl]phenyl]-3-phenoxy- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2003:874965 CAPLUS

DOCUMENT NUMBER: 139:364958

TITLE: Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 60 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030207872	A1	20031106	US 2002-42226	20020111 <--

PRIORITY APPLN. INFO.: US 2002-42226 20020111 <--

OTHER SOURCE(S): MARPAT 139:364958

AB Urea derivs. of formula A-NHCONH-B or pharmaceutically acceptable salts thereof [A = a substituted moiety of up to 40 carbon atoms of the formula -L-(M-L1)q; where L = a 5 or 6 membered cyclic structure bound directly to D; L1 = a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur; B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared These compds. are useful for raf mediated diseases, in particular a cancerous cell growth mediated by raf kinase. All compds. exemplified, e.g. N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea, displayed IC50 of between 1 mM and 10 μM.

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ω-carboxyaryl substituted di-Ph ureas as raf

kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)

RN 284461-67-2 CAPLUS

CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS

CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS

CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 284461-71-8 CAPLUS

CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:757329 CAPLUS
DOCUMENT NUMBER: 139:276918
TITLE: Preparation of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 61 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030181442	A1	20030925	US 2001-993647	20011127 <--
PRIORITY APPLN. INFO.:			US 2001-993647	20011127 <--

OTHER SOURCE(S): MARPAT 139:276918

AB Aryl ureas of formula A-NHCONH-B [A = a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L1)q (where L = a 5 or 6 membered cyclic structure bound directly to D, L1 comprises a substituted cyclic moiety having at least 5 members; M = a bridging group having at least one atom; q = an integer of from 1-3; each cyclic structure of L and L1 contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur); B = a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur] are prepared These urea derivs. are useful for treating raf mediated diseases, in particular cancerous cell growth mediated by raf kinase. Thus, N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. Thus, a solution of 4-bromo-3-(trifluoromethyl)phenyl isocyanate (8.0 g, 30.1 mmol) in CH2Cl2 (80 mL) was added dropwise to a solution of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (7.0 g, 28.8 mmol) in CH2Cl2 (40 mL) at 0°, stirred at room temperature for 16 h, and filtered to give, after washing the yellow solids, washing with CH2Cl2 (2 + 50 mL), and drying under reduced pressure (approx. 1 mmHg) at 40° to give N-[4-bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. All compds. exemplified showed IC50 between 1 nM to 10 μM against raf kinase.

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)

RN 284461-67-2 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS
CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 284461-71-8 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:590832 CAPLUS
DOCUMENT NUMBER: 139:149528
TITLE: Preparation of diphenylureas as RAF kinase inhibitors
INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 62 pp., Cont. of U. S. Ser. No. 42,203.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20030144278	A1	20030731	US 2002-283248		20021030 <--
US 7235576	B1	20070626	US 2002-42203		20020111 <--
PRIORITY APPLN. INFO.:			US 2001-367380P	P	20010112 <--
			US 2002-42203	A1	20020111 <--

OTHER SOURCE(S): MARPAT 139:149528
AB ADB [I; D = NHCONH; A = L(ML1)q; L = 5-6 membered cyclic structure bound directly to D; L1 = substituted cyclic moiety having ≥5 members, M = bridging group having ≥1 atom; q = 1-3; L, L1 contain 0-4 N, O, S; B = (substituted) up to tricyclic aryl, heteroaryl of ≤30 C atoms with ≥1 6-membered cyclic structure bound directly to D containing 0-4 N, O, S], were prepared Thus, 4-chloro-3-(trifluoromethyl)phenyl isocyanate in CH2Cl2 was added dropwise to a suspension of 4-[2-(N-methylcarbamoyl)-4-pyridyloxy]aniline (preparation given) in CH2Cl2 at

0°; the resulting mixture was stirred at room temperature for 22 h. to afford N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea. I inhibited RAF kinase in the range 1 nM-1 μM. I pharmaceutical compns. are claimed.

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diphenylureas as RAF kinase inhibitors)

RN 284461-67-2 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS
CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 284461-71-8 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



L6 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:615574 CAPLUS
DOCUMENT NUMBER: 137:169425
TITLE: Preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors

INVENTOR(S): Dumas, Jacques; Riedl, Bernd; Khire, Uday; Wood, Jill E.; Sibley, Robert N.; Monahan, Mary-Katherine; Renick, Joel; Gunn, David E.; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062763	A2	20020815	WO 2002-US3361	20020207 <--
WO 2002062763	A3	20021010		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20020165394	A1	20021107	US 2001-777920	20010207 <--
AU 2002238042	A1	20020819	AU 2002-238042	20020207 <--
AU 2004200722	A1	20040318	AU 2004-200722	20040224 <--
AU 2004200722	B2	20080110		

PRIORITY APPLN. INFO.:			
US 2001-777920	A	20010207	<--
US 1999-115877P	P	19990113	<--
US 1999-257266	B2	19990225	<--
US 1999-425228	B2	19991022	<--
AU 2000-25016	A3	20000112	<--
US 2001-758548	A2	20010112	<--
WO 2002-US3361	W	20020207	<--

OTHER SOURCE(S): MARPAT 137:169425
GI



II

AB Title compds., e.g., RNHCONHZOR1 [I; R = C6H4(CMe3)-3, 2-methoxy-5-trifluoromethylphenyl, 4-chloro-3-trifluoromethylphenyl, 2-methoxy-3-quinolyl, etc.; R1 = (un)substituted acylphenyl, -acylpyridinyl, etc.; Z = (un)substituted 1,3- or -1,4-phenylene] were prepared Thus, 4-(H2N)C6H4OC6H4(CONHMe)-4 (preparation given) was condensed with 3-(Me3C)C6H4NH2 and CO(OCCl3)2 to give title compound II. Data for biol. activity of title compds. were given.
IT 284461-67-2P 284461-68-3P 284461-70-7P

284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aryl-N'-[(acylphenoxy)phenyl]ureas as raf kinase inhibitors)

RN 284461-67-2 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS
CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 284461-71-8 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:545674 CAPLUS
DOCUMENT NUMBER: 135:137516

TITLE: Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases

INVENTOR(S): Bender, Steven Lee; Bhumralkar, Dilip; Collins, Michael Raymond; Cripps, Stephan James; Deal, Judith Gail; Nambu, Mitchell David; Palmer, Cynthia Louise; Peng, Zhengwei; Varney, Michael David; Jia, Lei

PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 237 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2001053274	A1	20010726	WO 2001-US1723		20010119	<--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
CA 2394703	A1	20010726	CA 2001-2394703		20010119	<--
US 20020103203	A1	20020801	US 2001-764306		20010119	<--
US 6635641	B2	20031021				
EP 1252146	A1	20021030	EP 2001-906592		20010119	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR						
BR 2001008025	A	20021105	BR 2001-8025		20010119	<--
JP 2003529558	T	20031007	JP 2001-553276		20010119	<--
MX 2002PA07102	A	20030128	MX 2002-PA7102		20020719	<--
US 20040092747	A1	20040513	US 2003-621979		20030717	<--
PRIORITY APPLN. INFO.:			US 2000-177059P	P	20000121	<--
			US 2001-764306	A3	20010119	<--
			WO 2001-US1723	W	20010119	<--

OTHER SOURCE(S): MARPAT 135:137516

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = CH, NH; Q = moiety such that ring A is (un)substituted mono- or bicyclic heteroaryl which has at least 2 carbon atoms in the heteroaryl ring system; X = CH2, O, S, NH; Y = CH2, O, S, provided at least one of X and Y = CH2 or X and Y form a cyclopropyl ring; R2-3 = H, Me, halo, CF3, CN; R4 = CONHR5, NHCOR6; where R5 = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R6 = (un)substituted aryl, heteroaryl, cycloalkyl, etc] are prepared Examples include synthetic procedures for over 150 compds., 11 biol. assays and 3 sample formulations. For instance, 3-mercaptobenzoic acid was treated with α-chloro-N-methoxy-N-methylacetamide followed by carbodiimide coupling to 2-methyl-6-aminoquinoline to give II. II was converted to a β-thiono-ketone with thioacetanilide/n-BuLi followed by treatment with hydrazine to give pyrazole III. III gave 85% inhibition of an lck protein tyrosine kinase at 5 μM and had Ki = 2.21 nM for VEGF-R2Δ50. Treatment of cancer as well as other disease states

associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis are claimed uses of the invention.

IT 351323-37-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of heteroarylbenzamides used for inhibiting protein kinases)

RN 351323-37-0 CAPLUS

CN Benzamide, 3-phenoxy-N-[3-[(1H-pyrazolo[3,4-d]pyrimidin-4-ylthio)methyl]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:772609 CAPLUS

DOCUMENT NUMBER: 133:335157

TITLE: Benzopyrrolone derivatives and related compounds as inhibitors of c-jun n-terminal kinases (JNK)

INVENTOR(S): Salituro, Francesco Gerald; Bemis, Guy W.; Wilke, Susanne; Green, Jeremy; Cao, Jingrong; Gao, Huai; Harrington, Edmund Martin

PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA

SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064872	A1	20001102	WO 2000-US10866	20000421 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1175399	A1	20020130	EP 2000-926272	20000421 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

US 20030153560	A1	20030814	US 2001-35823		20011023 <--
US 20080033022	A1	20080207	US 2007-729420		20070328 <--
PRIORITY APPLN. INFO.:			US 1999-130752P	P	19990423 <--
			WO 2000-US10866	W	20000421 <--
			US 2001-35823	B1	20011023 <--

OTHER SOURCE(S): MARPAT 133:335157

GI



I



II



III

AB Benzopyrrolone derivs. and related compds. I (T = N or CR1; U = N or CR2; V = N or CR3; X = N or CR4; Y = CH2Q1, COQ1, CONHQ1, CO2Q1, SO2Q1 or SO2NHQ1 {where Q1 = (un)substituted C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-14 membered bicyclic or tricyclic (non)aromatic carbocyclic or heterocyclic ring system}; W = N or C {wherein when W = N, R8 = lone pair of electrons and when W = C, R8 = R7} ; R1 = NHR5, OR5, SR5, R5 {R5 = H, N(R)2, NHOH, NO2, CO2R, halo, (un)substituted C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-14 membered bicyclic or tricyclic (non)aromatic carbocyclic or heterocyclic ring system [R = C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-10 membered bicyclic (non)aromatic carbocyclic or heterocyclic ring system]}; R2, R3 or R4 = CONH2, CONHR, CON(R)2, NHR5, NHCH2R5, OR5, SR5, etc.; R7 = H, C1-6alkyl, C1-6alkenyl, (non)aromatic 5-7 membered ring or 9-14 membered bicyclic (non)aromatic carbocyclic or heterocyclic ring system) and II (Z = CH or N) or a pharmaceutically acceptable derivative or prodrug thereof, are disclosed as inhibitors of JNK, a mammalian protein kinase involved in cell proliferation, cell death, and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. Thus, benzopyrrolone III was prepared in seven steps with pyrrolone ring formation via reductive cyclization. The invention also provides pharmaceutical compns. comprising the inhibitors of the invention and methods of utilizing those compns. in the treatment and prevention of various disorders, e.g., inflammatory diseases, autoimmune diseases,

destructive bone disorders, proliferative disorders and neurodegenerative diseases. Exemplary compds. I had Ki values of < 1 μM for inhibition of JNK3 in vitro.

IT 303743-18-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of benzopyrrolone derivs. and related compds. as inhibitors of c-jun n-terminal kinases (JNK))

RN 303743-18-2 CAPLUS

CN Benzamide, N-[1-[(6-fluoro-4H-1,3-benzodioxin-8-yl)methyl]-2,3-dihydro-3-(hydroxyimino)-2-oxo-1H-indol-6-yl]-3-phenoxy- (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:493516 CAPLUS

DOCUMENT NUMBER: 133:120157

TITLE: Preparation of ω-carboxy(hetero)aryl substituted diphenyl ureas as raf kinase inhibitors

INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.

PATENT ASSIGNEE(S): Bayer Corporation, USA

SOURCE: PCT Int. Appl., 120 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042012	A1	20000720	WO 2000-US648	20000112 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2359510	A1	20000720	CA 2000-2359510	20000112 <--
CA 2359510	C	20070213		

CA 2549558	A1	20000720	CA 2000-2549558	20000112	<--
AU 2000025016	A	20000801	AU 2000-25016	20000112	<--
EP 1140840	A1	20011010	EP 2000-903239	20000112	<--
EP 1140840	B1	20060322			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY					
EE 200100368	A	20030415	EE 2001-368	20000112	<--
EE 4913	B1	20071015			
HU 2003000866	A2	20030728	HU 2003-866	20000112	<--
HU 2003000866	A3	20060428			
HU 225780	B1	20070828			
JP 2003526613	T	20030909	JP 2000-593580	20000112	<--
JP 3845792	B2	20061115			
BR 2000007487	A	20030923	BR 2000-7487	20000112	<--
CN 1219764	C	20050921	CN 2000-802685	20000112	<--
CN 1721397	A	20060118	CN 2005-10089504	20000112	<--
AT 321027	T	20060415	AT 2000-903239	20000112	<--
PT 1140840	T	20060531	PT 2000-903239	20000112	<--
ES 2255971	T3	20060716	ES 2000-903239	20000112	<--
EP 1690853	A1	20060816	EP 2005-28442	20000112	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
SK 285532	B6	20070301	SK 2001-988	20000112	<--
RU 2319693	C2	20080320	RU 2001-122818	20000112	<--
CZ 299125	B6	20080430	CZ 2001-2489	20000112	<--
TW 269791	B	20070101	TW 2000-89100575	20000407	<--
US 20010011135	A1	20010802	US 2001-773659	20010202	<--
US 20010011136	A1	20010802	US 2001-773675	20010202	<--
US 20010016659	A1	20010823	US 2001-773672	20010202	<--
US 20010027202	A1	20011004	US 2001-773658	20010202	<--
US 20010034447	A1	20011025	US 2001-773604	20010202	<--
IN 2001MN00799	A	20050304	IN 2001-MN799	20010705	<--
NO 2001003463	A	20010912	NO 2001-3463	20010712	<--
NO 321059	B1	20060306			
MX 2001PA07118	A	20021023	MX 2001-PA7118	20010712	<--
ZA 2001005751	A	20030714	ZA 2001-5751	20010712	<--
US 20020137774	A1	20020926	US 2001-907970	20010719	<--
BG 105763	A	20020329	BG 2001-105763	20010801	<--
BG 65158	B1	20070430			
BG 109688	A	20070531	BG 2001-109688	20010801	<--
HR 2001000580	A1	20020831	HR 2001-580	20010802	<--
US 20020042517	A1	20020411	US 2001-948915	20010910	<--
US 7351834	B1	20080401	US 2002-889227	20020108	<--
US 20030139605	A1	20030724	US 2002-71248	20020211	<--
HK 1045504	A1	20060407	HK 2002-106872	20020920	<--
AU 2004200722	A1	20040318	AU 2004-200722	20040224	<--
AU 2004200722	B2	20080110			
NO 2005005863	A	20010912	NO 2005-5863	20051209	<--
JP 2006328075	A	20061207	JP 2006-190034	20060711	<--
KR 2007020158	A	20070216	KR 2007-702656	20070201	<--
US 20080032979	A1	20080207	US 2007-845595	20070827	<--
IN 2007MN01633	A	20071214	IN 2007-MN1633	20071005	<--
US 20080153823	A1	20080626	US 2007-956111	20071213	<--
PRIORITY APPLN. INFO.:			US 1999-115877P	P 19990113	<--
			US 1999-257266	A2 19990225	<--
			US 1999-425228	A2 19991022	<--
			US 1999-115878P	P 19990113	<--
			AU 2000-25016	A3 20000112	<--
			CA 2000-2359510	A3 20000112	<--
			CN 2000-802685	A3 20000112	<--
			EP 2000-903239	A3 20000112	<--
			JP 2000-593580	A3 20000112	<--

WO 2000-US648	W	20000112 <--
IN 2001-MN799	A3	20010705 <--
KR 2001-708847	A3	20010712 <--
US 2001-948915	A1	20010910 <--
US 2002-889227	A1	20020108 <--

OTHER SOURCE(S): MARPAT 133:120157
GI



II

AB This invention relates to the preparation and use of (hetero)aryl ureas ANHCONHB [I; A = L(ML1)q; L = 5- or 6-membered (hetero)aryl, especially Ph or pyridinyl; M = bridging group; L1 = (hetero)aryl with at least one (un)substituted sulfamoyl, carboxy, or carbamoyl substituent; q = 1-3; B = certain (un)substituted mono- to tricyclic aryl or heteroaryl groups] for the treatment of raf mediated diseases, such as cancer (no data). Approx. 100 invention compds. and numerous intermediates were prepared For instance, 3-tert-butylaniline was coupled with bis(trichloromethyl)carbonate to form the isocyanate, followed by addition of 4-(3-N-methylcarbamoylphenoxy)aniline (preparation given) to afford the urea II.

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)

RN 284461-67-2 CAPLUS
CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS
CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 284461-71-8 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:493376 CAPLUS
DOCUMENT NUMBER: 133:120155
TITLE: Preparation of ω-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
INVENTOR(S): Riedl, Bernd; Dumas, Jacques; Khire, Uday; Lowinger, Timothy B.; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Monahan, Mary-Katherine; Natero, Reina; Renick, Joel; Sibley, Robert N.
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041698	A1	20000720	WO 2000-US768	20000113 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2359244	A1	20000720	CA 2000-2359244	20000113 <--
EP 1158985	A1	20011205	EP 2000-905597	20000113 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

MX 2001PA07120	A	20011101	MX 2001-PA7120		20010712 <--
US 20030139605	A1	20030724	US 2002-71248		20020211 <--
US 20030105091	A1	20030605	US 2002-86417		20020304 <--
AU 2004200566	A1	20040311	AU 2004-200566		20040213 <--
AU 2004200566	B2	20060817			
AU 2004200722	A1	20040318	AU 2004-200722		20040224 <--
AU 2004200722	B2	20080110			
US 20080027061	A1	20080131	US 2007-845597		20070827 <--
PRIORITY APPLN. INFO.:			US 1999-115878P	P	19990113 <--
			US 1999-257265	A2	19990225 <--
			US 1999-425229	A2	19991022 <--
			US 1999-115877P	P	19990113 <--
			US 1999-257266	B2	19990225 <--
			US 1999-425228	B1	19991022 <--
			AU 2000-25016	A3	20000112 <--
			AU 2000-27250	A3	20000113 <--
			WO 2000-US768	W	20000113 <--
			US 2001-948915	A1	20010910 <--
			US 2002-86417	B3	20020304 <--

OTHER SOURCE(S): MARPAT 133:120155

GI



II

AB The title compds. ADB [I; D = NHCONH; A = substituted moiety of up to 40 carbon atoms of the formula L(ML1)q (wherein L = 5-6 membered cyclic structure; L1 = substituted cyclic moiety having at least 5 members; M = bridging group having al least one atom; q = 1-3; each of L and L1 contains 0-4 members of the group consisting of N, O and S); B = (un)substituted up to tricyclic aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of N, O and S], useful in treating p38 mediated diseases, were prepared E.g., a multi-step synthesis of the urea II which showed IC50 of 1-10 μM against p38, was given. Compds. I are effective at 0.01-200 mg/kg/day (oral administration).

IT 284461-67-2P 284461-68-3P 284461-70-7P
284461-71-8P 284462-09-5P 284462-10-8P
284462-15-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ω-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)

RN 284461-67-2 CAPLUS

CN Benzamide, N-(4-fluorophenyl)-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-68-3 CAPLUS
CN Benzamide, N-[4-(dimethylamino)phenyl]-3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-70-7 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 284461-71-8 CAPLUS
CN Benzamide, 3-[4-[[[[2-methoxy-5-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-[4-(2-pyridinyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



RN 284462-09-5 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 284462-10-8 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 284462-15-3 CAPLUS
CN Benzamide, 3-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:753201 CAPLUS
DOCUMENT NUMBER: 131:351089
TITLE: Preparation of N-[(arylcarbonylamino)phenyl)benzamides and analogs as p38 kinase inhibitors
INVENTOR(S): Brown, Dearg Sutherland; Brown, George Robert
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9959959	A1	19991125	WO 1999-GB1489	19990511 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,

MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2328927	A1	19991125	CA 1999-2328927	19990511	<--
CA 2328927	C	20080219			
AU 9939399	A	19991206	AU 1999-39399	19990511	<--
AU 749293	B2	20020620			
BR 9910474	A	20010102	BR 1999-10474	19990511	<--
EP 1077931	A1	20010228	EP 1999-922290	19990511	<--
EP 1077931	B1	20041117			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200003353	T2	20010420	TR 2000-3353	19990511	<--
HU 2001002295	A2	20011128	HU 2001-2295	19990511	<--
HU 2001002295	A3	20021128			
JP 2002515476	T	20020528	JP 2000-549578	19990511	<--
NZ 507144	A	20021025	NZ 1999-507144	19990511	<--
RU 2215736	C2	20031110	RU 2000-131611	19990511	<--
AT 282590	T	20041215	AT 1999-922290	19990511	<--
CN 1185211	C	20050119	CN 1999-806143	19990511	<--
PT 1077931	T	20050331	PT 1999-922290	19990511	<--
ES 2232137	T3	20050516	ES 1999-922290	19990511	<--
PL 195600	B1	20071031	PL 1999-344164	19990511	<--
SK 286123	B6	20080407	SK 2000-1718	19990511	<--
IN 2000MN00475	A	20050715	IN 2000-MN475	20001006	<--
MX 2000PA10432	A	20010419	MX 2000-PA10432	20001024	<--
ZA 2000006030	A	20020125	ZA 2000-6030	20001025	<--
US 6579872	B1	20030617	US 2000-674560	20001102	<--
NO 2000005767	A	20001114	NO 2000-5767	20001114	<--
HK 1033754	A1	20050506	HK 2001-104301	20010620	<--
US 20030212068	A1	20031113	US 2003-424127	20030428	<--
US 6956037	B2	20051018			
IN 2004DE01130	A	20070112	IN 2004-DE1130	20040615	<--
IN 2004MN00348	A	20050429	IN 2004-MN348	20040618	<--

PRIORITY APPLN. INFO.:	GB 1998-10357	A	19980515 <--
	GB 1998-22483	A	19981016 <--
	WO 1999-GB1489	W	19990511 <--
	IN 2000-MN475	A3	20001006 <--
	US 2000-674560	A3	20001102 <--

OTHER SOURCE(S): MARPAT 131:351089

GI



II

AB R1CONHZNHCO(CH2)qR4 [I; R1 = (un)substituted Ph; R4 = (un)substituted cycloalkyl or -aryl; Z = (un)substituted 6-alkyl-1,3-phenylene or -6-halo-1,3-phenylene; q = 0-4] were prepared Thus, 2-methyl-5-nitroaniline was amidated by 3,4-(MeO)C6H3COCl and the reduced product amidated by 3-(O2N)C6H4COCl to give, after reduction and MeSO2Cl treatment, title compound II. Data for biol. activity of select I were given.

IT 250680-86-5P 250680-90-1P 250681-16-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[(arylcarbonylamino)phenyl)benzamides and analogs as p38 kinase inhibitors)

RN 250680-86-5 CAPLUS
CN Benzamide, N-[3-[[4-[(diethylamino)methyl]benzoyl]amino]-4-methylphenyl]-3-phenoxy- (CA INDEX NAME)



RN 250680-90-1 CAPLUS
CN Benzamide, N-[4-methyl-3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]phenyl]-3-phenoxy- (CA INDEX NAME)



RN 250681-16-4 CAPLUS
CN Benzamide, N-[3-[[3-[(6-chloro-4-pyrimidinyl)oxy]benzoyl]amino]-4-methylphenyl]-3-(4-morpholinyl)- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:425745 CAPLUS
DOCUMENT NUMBER: 131:87909
TITLE: Inhibition of p38 kinase activity using substituted heterocyclic ureas
INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932111	A1	19990701	WO 1998-US26080	19981222 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315720	A1	19990701	CA 1998-2315720	19981222 <--
AU 9919971	A	19990712	AU 1999-19971	19981222 <--
AU 739642	B2	20011018		
EP 1041982	A1	20001011	EP 1998-964709	19981222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001526223	T	20011218	JP 2000-525102	19981222 <--
MX 2000PA06233	A	20020918	MX 2000-PA6233	20000622 <--

PRIORITY APPLN. INFO.: US 1997-995750 A 19971222 <--
WO 1998-US26080 W 19981222 <--

OTHER SOURCE(S): MARPAT 131:87909
GI



II

AB A method for treatment of p38-mediated disease other than cancer comprises administration of ANHCONHB [I; A = substituted isoxazolyl, pyrazolyl, thienyl, furyl; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-(4-pyridinylthio)aniline with 3-tert-butyl-5-isoxazolyl isocyanate in toluene gave title compound II. In an in vitro p38 kinase assay, I displayed IC50 values of 1-10 μM.

IT 228999-76-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of p38 kinase-mediated diseases other than cancer)

RN 228999-76-6 CAPLUS

CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:425740 CAPLUS
DOCUMENT NUMBER: 131:73648
TITLE: Inhibition of raf kinase using substituted heterocyclic ureas
INVENTOR(S): Dumas, Jacques; Khire, Uday; Lowinger, Timothy Bruno; Paulsen, Holger; Riedl, Bernd; Scott, William J.; Smith, Roger A.; Wood, Jill E.; Hatoum-Mokdad, Holia; Johnson, Jeffrey; Lee, Wendy; Redman, Aniko
PATENT ASSIGNEE(S): Bayer Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932106	A1	19990701	WO 1998-US26078	19981222 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2315717	A1	19990701	CA 1998-2315717	19981222 <--
AU 9921989	A	19990712	AU 1999-21989	19981222 <--
EP 1047418	A1	20001102	EP 1998-965981	19981222 <--
EP 1047418	B1	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200002618	T2	20010420	TR 2000-2618	19981222 <--
JP 2001526220	T	20011218	JP 2000-525097	19981222 <--
HU 2001001704	A2	20011228	HU 2001-1704	19981222 <--
HU 2001001704	A3	20021228		
BR 9814374	A	20020514	BR 1998-14374	19981222 <--
CN 1149085	C	20040512	CN 1998-813623	19981222 <--
RU 2232015	C2	20040710	RU 2000-120184	19981222 <--
CN 1544420	A	20041110	CN 2004-10028655	19981222 <--
CN 100360507	C	20080109		
AT 300299	T	20050815	AT 1998-965981	19981222 <--
ES 2153340	T3	20060201	ES 1998-965981	19981222 <--
SK 286213	B6	20080506	SK 2000-963	19981222 <--
CZ 299156	B6	20080507	CZ 2000-2350	19981222 <--
NO 2000003232	A	20000821	NO 2000-3232	20000621 <--
NO 326150	B1	20081006		

MX 2000PA06226	A	20020311	MX 2000-PA6226		20000622	<--
IN 193672	A1	20040731	IN 2000-MN153		20000704	<--
BG 104597	A	20010228	BG 2000-104597		20000712	<--
BG 64984	B1	20061130				
HK 1029052	A1	20051118	HK 2000-107684		20001130	<--
AU 2003204708	A1	20030717	AU 2003-204708		20030613	<--
AU 2003204708	B2	20060525				
IN 2003MN00990	A	20050429	IN 2003-MN990		20031024	<--
PRIORITY APPLN. INFO.:			US 1997-996343	A	19971222	<--
			AU 1999-21989	A3	19981222	<--
			WO 1998-US26078	W	19981222	<--

OTHER SOURCE(S): MARPAT 131:73648

GI



II

AB A method for treatment of cancerous cell growth mediated by raf kinase comprises administration of urea derivs. ANHCONHB [I; A = substituted isoxazolyl, thienyl, thiadiazolyl, furyl, pyrazolyl, etc.; B = (substituted) mono-, di-, or tricyclic aryl, heteroaryl containing ≥1 5-6 membered aromatic structure containing 0-4 N, O, or S atoms]. Reaction of 4-phenyloxyphenyl isocyanate with 5-amino-3-tert-butylisoxazole in methylene chloride and heating at reflux temperature for 2 days gave title compound II. In an in vitro raf kinase assay, I displayed IC50 values of 1-10 μM.

IT 228999-76-6P 229000-21-9P 229000-25-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted heterocyclic ureas for treatment of cancerous cell growth mediated by raf kinase)

RN 228999-76-6 CAPLUS

CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-phenyl- (CA INDEX NAME)



RN 229000-21-9 CAPLUS

CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 229000-25-3 CAPLUS
CN Benzamide, 3-[4-[[[[5-(1,1-dimethylethyl)-3-isoxazolyl]amino]carbonyl]amino]phenoxy]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	154.28	340.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-22.14	-22.14

STN INTERNATIONAL LOGOFF AT 12:14:10 ON 07 JAN 2009